Podcasts about biotech

Biology may be the most important technology we take off planet, and Mario Maggio is building the hardware to prove it. The founder and CEO of Ambrosia Space joins Erum Azeez Khan and Karl Schmieder to explain why space bioprocessing has been stuck at 10 to 20 milliliters while bench scientists on Earth work at 250 milliliters and beyond, and what changes when a two and a half liter fed batch bioreactor with pH, dissolved oxygen, and total cell density sensors finally flies. Mario traces his path from aerospace propulsion and the Nova C lunar lander at Intuitive Machines to life support systems at Paragon and Axiom Space, and the realization that biology is the best CO2 scrubber, oxygen source, and chemical factory available for long duration missions where petroleum, farms, and easy resupply do not exist. The conversation digs into the engineering reality of fluids and gas in microgravity, why glass and ceramics never fly, the stainless steel and aluminum builds that replace them, the intentional and unintentional bacteria that come with building a bioreactor from scratch, and the NASA TechLeap winning CellSep continuous flow centrifuge that carries cells and secreted products into downstream processing without gravity. Mario also lays out the near term commercial case, from protein crystallization and monoclonal antibodies that behave differently in orbit to biofuels, vitamin production, medicines, and the big silver tanks that will feed astronauts because there will be no farms or cattle. He offers a candid read on artificial gravity gradients, why the Moon matters for building large vehicles in space, and why the same hardware that grows yeast for beer on Mars becomes the root of better biomanufacturing on Earth. Erum and Karl open with field notes from Bio Innovations North America in Omaha, including Midwest feedstock advantage, consortia momentum, the 30 percent of cost hiding in downstream processing, and why Smucker and Mars are actively scouting biotech innovators.Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and speak with the leaders and innovators using biology to change the world. Biology is the world's oldest technology, and it can be engineered. So, what are we growing?Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.messaginglab.com/groweverything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Chapters:(00:00:00) Why Biology Is the Best Commercial Case for Space(00:04:52) Bio Innovations North America and the Midwest Bioeconomy(00:07:21) Why Smucker and Mars Are Scouting Biotech Innovators(00:11:42) Inside Ambrosia Space: Bioreactors Built for Orbit(00:15:24) Scaling Past 150 Milliliters: Space Biology's Volume Problem(00:18:12) Stainless Steel, Leaks, and Why Glass Never Flies(00:21:36) NASA TechLeap and the CellSep Continuous Flow Centrifuge(00:26:08) Protein Crystals and Monoclonal Antibodies Made in Microgravity(00:31:22) Artificial Gravity, Lunar Bases, and Closing the Loop on Life Support(00:36:12) Quick Fire: Space Food Reality, HAL, and Biologics in OrbitLinks and Resources:Mario MaggioAmbrosia Space LinkedInAmbrosia Space111. Space Genes and Subway Scenes: Chris Mason on Planning Life's Next Big Leap93. Houston, We Have a Protocol: NASA's Kate Rubins on Biotech in Space187. One Small Step for a Microbe: Lynn Rothschild's Leap from Astrobiology to Bioengineering at NASA185. Brick Happens: Chris Maurer of Redhouse Studio Redesigns Remote Living for Earth and Mars152. Crystals in the Cosmos: Varda Rewrites Drug Formulation in MicrogravityGrow Everything LinkedInTopics Covered:space biomanufacturing, Ambrosia Space, orbital bioreactors, microgravity biotechnologyHave a question or comment? Message us here:Text or Call (804) 505-5553⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠Youtube⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠Grow Everything⁠⁠⁠⁠⁠⁠⁠⁠Music by: Nihilore Production by: Amplafy Media

What stops a promising platform from becoming an investable company? Kevin Walton, CEO of Baseimmune, has watched this from both sides, first as an investment banker and now running a 23-person biotech through a strategic pivot he led himself.He and Nick Capman get into beachhead decisions, why most preclinical teams run their experiments in the wrong order, how to keep a distributed team aligned when the CEO is an ocean away, and what investors actually weight when science, team, execution, and strategy are all on the table.Some of what comes up:Run the experiment that could kill the program first, before the supporting package existsAccumulating incremental data feels like de-risking and mostly isn'tPick fast and cheap on a CRO and you'll pay for it twiceBuild culture from where you actually are, not from where you'd like to beWrite decisions down, name one owner, and accept that ambiguity compounds faster at distanceHire a scientific advisory board that will argue with youScience gets you the meeting. Team, strategy, and execution decide what happens afterAbout Kevin WaltonKevin Walton is CEO and a board director at Baseimmune, a London biotech developing active immunotherapies for fibrosis with IPF as its lead indication. Before Baseimmune he held corporate development and business development leadership roles at Moderna, StrideBio, Curis, and G1 Therapeutics, following a start in investment banking and consulting. He holds a law degree from Duke University School of Law.About The FDA GroupThe FDA Group helps life science organizations rapidly access the industry's best consultants, contractors, and candidates. Our resources assist in every stage of the product lifecycle, from clinical development to commercialization, with a focus on staff augmentation, auditing, remediation, QMS, and other specialized project work in Quality Assurance, Regulatory Affairs, and Clinical Operations. Learn more: https://www.thefdagroup.com/

Good morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of pivotal advancements and strategic maneuvers shaping the landscape of drug development and patient care. Bayer's Kerendia, known generically as finerenone, has achieved its third FDA approval, this time targeting chronic kidney disease linked with type 1 diabetes. This small molecule mineralocorticoid receptor antagonist plays a critical role in mitigating fibrosis and inflammation—key factors in chronic kidney disease progression. Given the high prevalence of kidney complications in diabetic patients, this approval marks a significant step forward in managing such conditions. Its mechanism offers a novel approach to addressing cardiovascular and metabolic disorders, underscoring its vital role in contemporary therapeutic strategies. In regulatory advancements, AstraZeneca and Daiichi Sankyo's Enhertu has secured approval from NICE for treating HER2-low breast cancer. This marks a significant transition toward precision medicine, allowing the NHS to provide more targeted cancer therapies. Enhertu, an antibody-drug conjugate, exemplifies the shift towards precision oncology by delivering cytotoxic agents directly to cancer cells expressing HER2, thus opening new avenues for personalized treatment strategies. Japan's MHLW has given the green light to GSK's Shingrix in prefilled syringe form for shingles prevention. As a recombinant zoster vaccine enhanced by an adjuvant system, Shingrix represents cutting-edge vaccine technology aimed at strengthening immune responses against the varicella-zoster virus. This approval not only broadens preventative measures but also highlights advancements in vaccine delivery systems. Novo Nordisk's collaboration with Orbis Medicines is another noteworthy development, focusing on oral macrocycle therapies for cardiometabolic conditions—a partnership with potential milestones valued at $1.4 billion. This move aligns with Novo Nordisk's strategic push into small molecule drug discovery to address unmet needs in cardiovascular and metabolic disorders, echoing a broader industry trend towards innovative therapeutic approaches. Meanwhile, Roche has ventured into an agreement with Dualitas Therapeutics to develop bispecific antibody platforms for autoimmune diseases. With an upfront payment of $36.5 million and potential milestone payments reaching $1 billion, this collaboration underscores the burgeoning interest in bispecific antibodies' capacity to target dual antigens simultaneously—offering promising new pathways for treating complex immunological conditions. On the clinical trial front, Roche's Lunsumio has met its Phase 3 primary endpoint, showcasing improved progression-free survival in patients with relapsed or refractory follicular lymphoma. This bispecific antibody exploits the immune system by targeting CD20 on B-cells while engaging CD3 on T-cells, highlighting its potential as an effective option for difficult-to-treat cancers. Conversely, Longeveron's laromestrocel faced setbacks in its Phase 2b trial for hypoplastic left heart syndrome—a reminder of the complexities inherent in developing cell therapies for cardiovascular diseases. Such challenges highlight the critical need for innovative approaches and continued perseverance within clinical development. Regulatory scrutiny remains a pertinent issue as evidenced by the FDA's warning letter to Bausch & Lomb over contamination concerns. This action emphasizes ongoing challenges within ophthalmology manufacturing standards and regulatory compliance—critical aspects that demand rigorous attention to ensure patient safety. These developments collectively reflect an industry characterized by dynamic scientific advancements and strategic collaborations aimed at addressing pressing health challenges through cutting-edge drug development and precision medicine. As companies continue to invest in innovative research and form strategic alliances, these efforts offer significant promise for improving patient outcomes through more effective and targeted therapies. The evolving regulatory landscapes and technological advancements will undoubtedly shape these trends further, offering new opportunities for growth and breakthroughs in patient care. The commitment to overcoming complex challenges remains at the forefront of industry priorities as stakeholders strive to deliver impactful treatments to patients worldwide. Thank you for tuning into Pharma Daily; stay with us as we continue to explore these transformative developments shaping the future of healthcare science.Support the show

Meet Noah: The AI Robot Delivering Your Next Meal w/ Steve Burns of NoTip - AZ TRT S07 EP15 (297) 9-13-2026       What We Learned This Week Food delivery may be ready for a robotics makeover. NoTip is testing a model where an EV gets the food close to the customer's home and an autonomous robot completes the final delivery. The expensive part of a delivery isn't necessarily the food—it's the last mile. Restaurants and consumers can face significant costs from today's delivery model. NoTip is trying to use automation and EVs to change that equation. Physical AI is moving into the real world. LiDAR, cameras, GPS, sonar and RTK positioning allow robots to understand and navigate physical environments—not just digital ones. The EV revolution isn't just about cars. Purpose-built electric vehicles can be dramatically smaller and lighter than conventional cars, potentially changing the economics of businesses that operate fleets all day. The future of autonomous delivery may involve two vehicles—not one. The delivery vehicle gets the order to the neighborhood, while a smaller robot handles the final few yards to the front door. That combination could allow companies to rethink how the entire delivery process works.     Guest: Steve Burns — Founder, NoTip Stephen S. Burns is a serial entrepreneur and technology executive with more than three decades of experience building disruptive companies across automotive, electric vehicles, telecommunications, and software. He is the founder of Lordstown Motors, where he served as Chairman and CEO, leading the acquisition and transformation of the former General Motors Lordstown Assembly Plant into an electric vehicle manufacturing facility. He also founded Workhorse Group (NASDAQ: WKHS), an early pioneer in commercial electric vehicles and last-mile delivery technology, helping lay the foundation for today's commercial EV market. Prior to his work in electric mobility, Burns founded Mobile Voice Control, a pioneering speech recognition software company for smartphones that was acquired by Nuance Communications. Throughout his career, he has successfully founded, scaled, and exited multiple technology ventures, commercializing innovative products that have advanced mobile communications, enterprise software, and transportation technologies. He is widely recognized for identifying emerging technologies and transforming them into industry-leading businesses.     Company: NoTip Location: Mason, Ohio, outside Cincinnati Industry: Autonomous vehicles / Physical AI / Food delivery / EV technology https://notip.ai/index/home   NoTip is transforming food delivery in Mason, Ohio NoTip is redefining food delivery in Mason Ohio. We operate as a 3rd party delivery platform. We feature local restaurants on our platform and then use electric vehicles driven by our uniformed team members combined with and our specially designed robots to pick up your food and deliver it to your doorstep.  This approach enables dramatically lower costs, faster service, and greater reliability- while removing common pain points like tipping, hidden fees, food markups, and concerns around strangers on your doorstep.  Simple, Sleek, Easy-To-Use App Order your favorite food in seconds with NoTip's powerful, east-to-use app. Order from your favorite local restaurants and track your delivery in real time as our uniformed team member and advanced robotic system brings your food directly to your doorstep. No tipping, no food mark-ups—just seamless, reliable delivery at the tap of a button. Download the NoTip app today and experience the future of food delivery.     Segment 1 — Meet Noah: The Robot Changing Food Delivery Steve Burns introduces NoTip, a new autonomous food-delivery company operating out of Mason, Ohio. The company has spent approximately four years in stealth mode developing its technology. NoTip officially went live in the summer of 2026. The company's technology centers around Noah, an autonomous delivery robot built in-house. Noah is an example of what Steve describes as Physical AI—AI that doesn't just exist in software but interacts with the physical world. The company is essentially taking on the traditional food-delivery model represented by companies such as DoorDash and Uber Eats. Customers order through an app and pay before the delivery. Instead of a gig worker delivering the order, NoTip uses autonomous vehicles and robots. The initial focus is suburban food delivery. The basic proposition is simple: people are willing to pay for convenience. Steve uses Uber as an example of how consumers have demonstrated that they'll pay for convenience when the service solves a problem. NoTip's future delivery system combines: An autonomous EV Noah, the smaller autonomous robot The robot carrying the food from the vehicle to the customer's home The delivery vehicle can deploy the robot using a ramp. Noah uses a combination of: LiDAR Sonar GPS Cameras Mapping technology The robot has gone through thousands of modifications and improvements during development. Current testing includes a safety driver behind the wheel who can take over and make the delivery if the autonomous system encounters a problem. The Technology Business Steve points out the enormous valuations attached to technology-driven companies. DoorDash has reached a market capitalization far larger than many traditional vehicle manufacturers. His larger point: the software and technology layer can be more valuable than the physical vehicle itself. NoTip's concept is designed to be easy for consumers to understand: The delivery vehicle comes to your neighborhood. A small robot gets out. The robot takes your food to the door. Steve compares the concept to the familiar infrastructure of a UPS delivery fleet—but with autonomous technology replacing much of the human delivery process. Why Does Food Delivery Cost So Much? The NoTip Model NoTip plans to charge a flat $6 delivery fee. Traditional food-delivery services can charge restaurants significant fees, sometimes approaching 30%, depending on the arrangement. Those costs can ultimately be reflected in higher menu prices and delivery costs for consumers. Steve believes the current food-delivery model has become too expensive for restaurants, consumers and other participants in the food ecosystem. Automation could potentially change the economics of last-mile delivery. EV Economics Electric vehicles have substantially lower energy costs than gasoline-powered vehicles. Lower operating costs become particularly important in a delivery business where vehicles may operate for many hours every day. Amazon has already demonstrated the use of electric delivery vans through its Rivian fleet. NoTip is looking beyond conventional delivery vans toward smaller, purpose-built EVs. The Future NoTip Vehicle Steve envisions a future NoTip delivery vehicle that could be a three-wheel EV, more similar to a large motorcycle than a traditional automobile. The goal is to make the vehicle: Lightweight Efficient Less expensive to operate Purpose-built for delivery A lighter vehicle requires less energy to move, potentially helping reduce operating costs. Why Automation Could Matter Steve discusses some of the challenges and safety concerns associated with the current gig-worker delivery model. NoTip's objective is to create a delivery system that emphasizes consistency, safety and efficiency. The technology isn't simply about eliminating a driver—it is about redesigning the entire last-mile delivery process. Segment 2 — From EVs to Robots Steve Burns' EV Background Steve brings significant experience from the electric-vehicle industry. His background includes work with companies such as: Workhorse Lordstown Motors His experience gives him an understanding of: EV development Manufacturing Supply chains Automotive regulations Vehicle technology The challenges of bringing new transportation technology to market Lordstown Motors Steve discusses the bankruptcy of Lordstown Motors. He subsequently acquired intellectual property and physical assets from the company. That included EV-related assets and vehicles that could be useful in developing future technology. NoTip's Current Vehicles The company is experimenting with multiple prototype configurations. Some of the current vehicles are modified BMW i3s. These conventional vehicles weigh roughly 2,000 pounds. Steve discusses future vehicles that could be much lighter. One concept is approximately 1,500 pounds, including the battery. The battery system is designed to provide roughly 10 hours of operating time. Building the Robot Noah has gone through multiple prototype versions. The team has learned from putting the robots into real-world environments. One of the challenges is that a robot can't assume every customer's property looks the same. It needs to navigate things such as: Rakes Landscaping Driveways Sidewalks Other obstacles The robot can also be modified for different environments, including the use of snow tires for winter conditions. The Technology Behind Noah Noah combines several technologies to understand its environment. Sensors LiDAR Sonar Cameras GPS Optical sensors The vehicle and robot use these systems to understand and map their surroundings. RTK — Real-Time Kinematic Positioning Steve discusses RTK, or Real-Time Kinematic positioning. The technology can dramatically improve location accuracy and allow the system to map an area with extremely high precision—down to approximately the centimeter level under suitable conditions. That matters when a robot needs to know: "Exactly where am I on this property?" rather than simply: "I'm somewhere near this address." A Bigger Robotics Trend Steve points out that similar technology is being used in other industries. One example is autonomous robotic lawnmowers. As sensors, computing power and other components become less expensive, technologies that once required expensive R&D can become commercially practical. NoTip is essentially applying some of those technologies to food delivery. Segment 3 - How Does an Autonomous Delivery Actually Work? Getting to the House Google Maps can be used to determine the vehicle's driving route. The vehicle handles the trip from the restaurant to the customer's neighborhood. The robot then handles the final portion of the delivery on the customer's property. Current Regulatory Approach During the current testing phase, there is still a driver behind the wheel of the autonomous vehicle. This allows NoTip to operate within the existing regulatory framework while testing its autonomous technology. The robot itself operates on the customer's property after receiving permission. Customer Permission Customers agree to allow the robot onto their property through the NoTip app. The system can collect information such as: Email address Phone number Property permission This creates a defined interaction between the customer and the autonomous delivery system. What's Next for NoTip? NoTip is currently testing and refining its technology. The company expects to continue improving both the robot and the vehicle platform. Future plans include: Additional cities Purpose-built EVs More autonomous robots Expanded manufacturing capabilities Steve discusses eventually building a 22,000-square-foot facility for manufacturing and development. That facility could support production of the company's three-wheel EV and robotic delivery systems. Phoenix is one city Steve has identified as a potential future market. NoTip expects to announce its next city in fall 2026. The Bigger Idea The roads and delivery infrastructure already exist. Consumers already: Order food through apps Pay electronically Expect delivery Pay for convenience The question becomes: Can technology make the last mile faster, safer and less expensive? That's the problem NoTip is trying to solve.         Tech Topic: https://brt-show.libsyn.com/category/Tech-Startup-VC-Cybersecurity-Energy-Science  Best of Tech: https://brt-show.libsyn.com/size/5/?search=best+of+tech   'Best Of' Topic: https://brt-show.libsyn.com/category/Best+of+BRT      Thanks for Listening. Please Subscribe to the AZ TRT Podcast.     AZ Tech Roundtable 2.0 with Matt Battaglia The show where Entrepreneurs, Top Executives, Founders, and Investors come to share insights about the future of business.  AZ TRT 2.0 looks at the new trends in business, & how classic industries are evolving.  Common Topics Discussed: Startups, Founders, Funds & Venture Capital, Business, Entrepreneurship, Biotech, Blockchain / Crypto, Executive Comp, Investing, Stocks, Real Estate + Alternative Investments, and more…    AZ TRT Podcast Home Page: http://aztrtshow.com/ 'Best Of' AZ TRT Podcast: Click Here Podcast on Google: Click Here Podcast on Spotify: Click Here                    More Info: https://www.economicknight.com/azpodcast/ KFNX Info: https://1100kfnx.com/weekend-featured-shows/  

Summer is a busy time for everyone, guests and listeners alike, so today we're taking stock. This is our Summer Recap — a clips episode pulling together the best moments from conversations you might have missed over the past few months.We'll hear from Randy Teel of Arvinas and Per Lundin of Evox on two very different ways of getting drugs to the brain, and Laurent Lévy of Nanobiotix on outsmarting the liver altogether. We'll meet the founders behind these companies, including Andy Parker of Step Pharma and Gene Mack of Gain Therapeutics, and the unlikely paths that got them there. We'll dig into the science of nonsense mutations with Nerissa Kreher of Alltrna, circular RNA with Lu Gao of Therorna, and a cancer target hiding in human genetics. And we'll close with what these leaders think success actually looks like, years from now.So sit back, and let's revisit some of our favourite moments from the summer.02:32 Solving the delivery problem08:39 Founder journeys15:13 Platform science24:41 Business, money, and geopolitics32:28 Looking aheadInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Episode 204: The first PROTAC is here. What comes next in protein degradation?Episode 205: Turning cancer cell dependencies into targeted therapiesEpisode 208: Gain Therapeutics: a first-in-class, disease-modifying therapy for Parkinson'sEpisode 209: Why Western pharma is sleeping on China's circular RNA revolutionEpisode 211: Beyond biology: Nanobiotix's physics-first approach to cancerEpisode 213: How Evox Therapeutics is targeting CNS diseases with exosomesEpisode 214: Rewriting the rules of genetic medicine with tRNA therapeutics

Hi everyone, it's been a while! I decided to do an update, sharing details about what took me away from the channel. I also talk about different themes that have emerged in that time as well as themes that went away. Finally, I touch on all the companies I had invested in over the years, providing brief updates on each one. While it was a good way to lose money, there were some lessons in it, which I share at the end of the episode. $KOD (23:20) is one company I am excited about for an upcoming readout. DAYBREAK is a phase 3 clinical trial comparing Zenkuda (tarcocimab), KSI-501 (VEGF + IL-6 inhibition) and Aflibercept 2mg in wet AMD. This indication is a massive opportunity and is on track to release results in September 2026. The company trading at a $2B market cap today, which I think has potential to go much higher on a positive result. Disclaimer: All opinions expressed by Matt (or his guests) in this podcast are solely his (their) opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt's opinions are based upon information he considers reliable, but Matt (nor his guests) cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt (nor his guests) is/are not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt (nor his guests) does/do not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast. #biotech This podcast is powered by Pinecast.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of dynamic and significant advancements across the industry, from strategic acquisitions to regulatory shifts and scientific innovations. In a bold move, Novartis has acquired Sironax's blood-brain barrier delivery platform for $125 million. This acquisition marks a strategic enhancement in Novartis's ability to deliver therapies directly to the brain, overcoming one of the most formidable challenges in treating neurological disorders. The potential to deliver antibodies and other therapeutic agents effectively across this barrier could lead to groundbreaking treatments for conditions like Alzheimer's disease and multiple sclerosis. This reflects a broader industry trend emphasizing improved drug delivery systems to boost treatment efficacy and patient outcomes. On the clinical advancement front, Sling Therapeutics has raised $123 million in a Series C funding round aimed at propelling its oral therapy for thyroid eye disease forward. Unlike traditional intravenous treatments, this oral therapy offers a more convenient option for patients, potentially improving adherence and quality of life. Meanwhile, Circle Pharma's $92.5 million Series E funding will support the development of its cyclin D1 inhibitor for breast cancer, showcasing innovation in oncology through the use of macrocycles that could provide more effective treatments with fewer side effects. Investments in AI and machine learning are also reshaping the landscape. Ginkgo Bioworks' collaboration with Novo Nordisk to construct an autonomous lab highlights the increasing role of automation in optimizing R&D productivity. Mithrl's $20 million Series A round further underscores this shift, focusing on developing an AI infrastructure platform for streamlined biopharma drug discovery processes. The regulatory environment continues to evolve with notable challenges. BioMarin has discontinued Phase 2 development of Voxzogo in Noonan syndrome due to shifting treatment landscapes, illustrating the dynamic nature of therapeutic development. Similarly, Novartis's halt on its TREM2 stabilizer after a Phase 2 failure in ALS research points to the complexities inherent in neurodegenerative disease studies. Maat Pharma faced a setback when its appeal was rejected regarding the EMA's negative opinion on its graft-versus-host disease candidate, Xervyteg. This instance highlights the stringent regulatory hurdles companies must navigate to bring novel therapies to market. Amid these developments, Gilead Sciences is strategically expanding into oncology and inflammation. Through several acquisitions, Gilead has diversified its portfolio significantly, emphasizing oncology as a central focus area given its high potential for addressing unmet needs and offering substantial returns on investment. Legend Biotech's appointment of Ingrid Zhang as CEO signals a strategic push into the competitive CAR-T cell therapy market. These therapies represent a revolutionary approach in personalized medicine for cancer treatment, with Legend positioning itself for growth and innovation. Bristol Myers Squibb and Ono Pharmaceutical are preparing to contest Amgen's efforts to launch a biosimilar for their oncology blockbuster Opdivo. This reflects broader competitive dynamics within the biologics market where biosimilars promise more cost-effective options, potentially reshaping market shares and pricing strategies. Manufacturing innovations are also at play with Ori Biotech securing a $120 million deal for an automated production platform in cell therapy manufacturing. Such advancements are crucial as cell therapies become more mainstream, necessitating scalable solutions that maintain quality while meeting demand. Operational expansions continue as Reckitt Benckiser allocates $600 million to upgrade its US operations, fostering innovation across health and hygiene product lines—an industry trend towards integrating R&D with manufacturing prowess to drive new product development. While challenges persist—illustrated by Novartis's multiple trial failures—the pharmaceutical and biotech sectors remain resilient with adaptive strategies focused on innovation. The ongoing advancements underscore not only scientific exploration but also strategic maneuvering amidst evolving regulatory landscapes. As AI reshapes talent acquisition strategies and technological advancements accelerate drug discovery processes, companies must navigate complex global health ecosystems poised for transformative growth. The focus remains on improving patient outcomes through cutting-edge science while balancing innovation with strategic realignment. Thank you for tuning into Pharma Daily—where we keep you abreast of pivotal industry shifts shaping the future of healthcare. Join us again tomorrow as we continue exploring these exciting developments impacting patient care worldwide.Support the show

Elástica e rica em colágeno, pele de tilápia vira curativo biológico nas mãos de cientistas da Universidade Federal do Ceará. A biotecnologia desenvolvida pelo Núcleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM) consiste em um curativo de pele liofilizada, que é uma desidratação sob congelamento e vácuo. No episódio desta semana do podcast de Biotech & Health, o diretor do NPDM, professor Odorico de Moraes detalha os primeiros passos da inovação e as pesquisas em curso para novas aplicabilidades com a matéria-prima.

What happens when the way you normally do business doesn't translate across borders?In this episode, host Elaine Hamm, PhD, welcomes back Rod Beeler, Executive Partner at Magellan Executive Partners, for a conversation about navigating cultural differences in international business. Drawing from Rod's extensive experience working across Europe, the Middle East, Africa, Asia, and Australia, they explore how communication styles, relationship-building, and expectations can vary dramatically from one culture to another - and why understanding those differences matters when building global partnerships.In this episode, you'll discover:Why communication styles, business etiquette, and expectations can differ significantly across cultures, and how assumptions can derail otherwise promising relationships.How taking time to understand cultural norms and build trust can make international business development, networking, and dealmaking more effective.Why research, curiosity, adaptability, and a willingness to understand the person behind the business can help leaders navigate cross-cultural relationships.Tune in to learn how greater cultural awareness can help you build trust, communicate more effectively, and create stronger business relationships across borders.Links:Connect with Rod Beeler and learn about Magellan Executive Partners.Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine.Check out Caterpillar and the Latitude podcast.Connect with Ian McLachlan, BIO from the BAYOU producer.Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant strides and strategic maneuvers reshaping the landscape of healthcare and drug development. Kicking things off, GlaxoSmithKline (GSK) has made headlines with its acquisition of Chimagen Biosciences' trispecific T cell engager technology, targeting multiple myeloma. This move, valued at up to $750 million, highlights GSK's strategic focus on expanding its oncology pipeline through cutting-edge immunotherapeutic approaches. Trispecific T cell engagers are an emerging class of biologics that bind to three different targets simultaneously, effectively arming the immune system to recognize and destroy cancer cells more efficiently. This acquisition not only strengthens GSK's position in the competitive oncology market but also addresses a significant need for more effective multiple myeloma treatments. In parallel, Curium has achieved a notable milestone with the FDA approval of Bexlutry, a radioligand therapy for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This therapy utilizes radioactive isotopes attached to molecules that specifically target cancer cells, delivering radiation directly while minimizing harm to healthy tissue. The approval of Bexlutry is a crucial development in oncologic care, expanding treatment options for patients dealing with complex and heterogeneous tumors. It underscores the growing role of targeted radiotherapies in providing precision medicine solutions. On the financial front, Electra Therapeutics is gearing up for an initial public offering (IPO) to raise $325 million. The proceeds are intended to advance its late-stage clinical trials for severe hemophagocytic lymphohistiocytosis (SHLH), a rare autoimmune condition. This move reflects a broader trend among biotech companies turning to public markets to support niche therapeutic areas with high unmet needs and potential orphan drug status benefits. Turning to clinical advancements, Corbus Pharmaceuticals has reported encouraging Phase 1b data for CRB-913, which employs CB1 inverse agonism in combating obesity. By modulating endocannabinoid activity linked to appetite and energy balance, this approach offers a promising direction for managing metabolic disorders. Simultaneously, CSL Seqirus has shared Phase 3 results showcasing the superior efficacy of its MF59-adjuvanted cell-based quadrivalent influenza vaccine in older adults, highlighting ongoing innovations in vaccine technologies tailored for vulnerable populations. The FDA's regulatory landscape is also evolving with the launch of Operation Trialblazer. This initiative seeks to streamline early-phase U.S. clinical trials through expedited IND application processes, facilitating faster transitions from research to clinical applications and fostering innovation by reducing bureaucratic hurdles. Meanwhile, the FDA is preparing for potential psychedelic medicine approvals, ensuring robust oversight frameworks are in place as these therapies near market availability. Yet, as always in drug development, challenges persist. Novo Nordisk's decision to terminate its GLP-1 obesity drug partnership with Ascendis following unsatisfactory results exemplifies the inherent risks even promising preclinical data can present. Similarly, setbacks faced by Axoltis Pharma and Eli Lilly with their neurological and metabolic candidates reinforce the complexities of translating scientific hypotheses into viable therapies. Sanofi has taken significant strategic steps as well by divesting 20 older medicines and three manufacturing sites to Cheplapharm. This decision aligns with Sanofi's focus on innovation under CEO Paul Hudson's leadership and allows the company to reallocate resources towards groundbreaking therapies. In diagnostic advances, the FDA's approval of Telix's Pixclara marks a breakthrough for brain cancer imaging. Being the first FET-PET imaging drug approved for gliomas, Pixclara could significantly enhance diagnostic accuracy and treatment planning for these challenging tumors. These developments underscore a transformative period where scientific innovation is paired with strategic regulatory adjustments to navigate complex market dynamics. As companies continue adapting to these changes, their ability to innovate while addressing safety and efficacy concerns will be critical in advancing therapeutic frontiers and improving patient outcomes across diverse medical landscapes. As always, we'll be here at Pharma Daily to keep you informed on these pivotal changes shaping our industry's future. Thank you for tuning into today's episode of Pharma Daily. Keep innovating and stay informed!Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today's episode delves into some of the latest breakthroughs, regulatory updates, and strategic maneuvers reshaping the landscape of drug development and patient care. Starting with remarkable advancements in drug approvals, Scholar Rock's Isembldy (apitegromab), a monoclonal antibody designed to inhibit myostatin, has secured FDA approval for treating spinal muscular atrophy. This approval came after successful Phase 3 trials and marks a significant milestone in managing neuromuscular diseases. By targeting the myostatin pathway, which regulates muscle growth, Isembldy offers hope for improved motor function in patients suffering from this debilitating condition. Meanwhile, Pharming's Joenja (leniolisib) received an expanded label from the FDA, now approved for pediatric patients aged four and older with activated phosphoinositide 3-kinase delta syndrome, reflecting ongoing efforts to tackle rare autoimmune disorders. Telix Pharmaceuticals has also made strides with the approval of Pixclara (floretyrosine F 18) for PET imaging of glioma, enhancing diagnostic precision for both adult and pediatric brain cancer patients. In clinical trial successes and challenges, GSK and Hansoh Pharmaceutical reported that their antibody-drug conjugate, risvutatug rezetecan, significantly reduced the risk of death in Phase 3 trials for relapsed small-cell lung cancer by 54%. This underscores the potential of targeted therapies in oncology, especially where second-line treatments have been limited. AstraZeneca's Tagrisso (osimertinib), meanwhile, continued to demonstrate its efficacy with a notable reduction in death risk in early-stage EGFR-mutated non-small cell lung cancer at an eight-year follow-up, reinforcing its value as an adjuvant therapy. However, AstraZeneca faced setbacks with camizestrant's Phase 3 trial failing to meet primary endpoints in estrogen receptor-positive breast cancer. A similar challenge arose with Enhertu (trastuzumab deruxtecan) in HER2-mutant non-small cell lung cancer, indicating ongoing difficulties in developing effective combination therapies. Turning to strategic business developments, Johnson & Johnson's decision to divest its orthopedics unit DePuy Synthes to Apollo Equity Management for $20 billion reflects a strategic refocus on core areas like pharmaceuticals and medical devices. Similarly, Novo Nordisk's rebranding as 'Novo' signals an effort to strengthen its competitive stance against Eli Lilly within the GLP-1 agonist market, crucial for managing metabolic disorders such as diabetes. In collaborations and licensing deals aimed at broadening access to healthcare innovations, Bio Usawa's partnership with Axmed is set to enhance access to affordable biologic medicines across Africa, a vital step towards expanding healthcare reach in underserved regions. In oncology research advancements, Owkin has licensed its AI-driven K Pro scientist platform to Servier to accelerate drug discovery through artificial intelligence and machine learning applications. Regulatory challenges continue to shape industry dynamics. The FDA has postponed its decision on Exelixis's Zanzalintinib combined with Roche's Tecentriq for metastatic colorectal cancer until March 2027, reflecting rigorous scrutiny to ensure safety and efficacy. Meanwhile, Cellectis has opted to halt its allogeneic CAR-T programs amid increasing competition from in vivo approaches, showcasing strategic adaptability within the rapidly evolving field of cell therapy. In recent news focusing on mRNA technology and personalized cancer vaccines, Moderna's flu vaccine approval using mRNA technology marks a pivotal moment for this platform after facing skepticism over the years. Furthermore, Moderna and Merck have reported positive Phase 3 results for their personalized mRNA-based cancer vaccine—an advancement positioning them as leaders in personalized cancer immunotherapy following success in melanoma treatment. The sector remains dynamic as companies navigate these complex environments. Breakthroughs such as ivonescimab's success provide optimism for future innovations that could significantly enhance patient care and treatment outcomes across various diseases. The emphasis on mRNA technologies and personalized medicine heralds a new era of targeted therapies poised to redefine standards of care across multiple disease areas. As these initiatives progress, they hold potential not only for improving existing treatment paradigms but also for pioneering new frontiers in healthcare delivery. As these developments unfold, they highlight the industry's dual focus on advancing scientific innovation while navigating complex regulatory landscapes and competitive pressures. The implications are profound: promising enhanced patient outcomes through novel therapies while prompting strategic realignments among key industry players. These initiatives not only aim to improve existing treatment paradigms but also pioneer new frontiers in healthcare delivery.Support the show

Can precision oncology help identify cancer's genetic weaknesses and turn them into therapeutic opportunities? In this episode of "Rx for Biotech", host Chris Leidli speaks with Oren Gilad, CEO of Aprea Therapeutics, about the rapidly evolving field of synthetic lethality, DNA damage response, and targeted cancer therapies designed to exploit vulnerabilities in cancer cells. Oren shares how his scientific journey began at the University of Pennsylvania, where early experiments studying ATR helped shape the foundation for Aprea's current cancer drug development strategy. That work led to a central insight behind synthetic lethality: cancer cells with specific genetic mutations may become highly dependent on certain DNA repair and checkpoint pathways for survival. Aprea is developing a pipeline of precision oncology therapies focused on what Oren describes as multiple targets in one critical pathway, including WEE1, ATR, p53 reactivation, and DYRK1 inhibition. A major focus of the conversation is APR-1051, Aprea's investigational oral WEE1 inhibitor, which is being studied in patients with cancers carrying specific genetic alterations. Oren explains how WEE1 functions as a checkpoint in cell division, why cancer cells can become especially dependent on this pathway, and how inhibiting WEE1 may selectively target tumor cells while aiming to preserve a wider therapeutic window. This episode is especially relevant for anyone interested in precision medicine, targeted cancer therapy, DNA repair, synthetic lethality, oncology clinical trials, cancer biomarkers, and the future of drug development. Subscribe to Rx for Biotech podcast for conversations with biotech CEOs, scientists, physicians, and industry leaders developing the next generation of personalized medicines. This podcast is for educational purposes only and should not be interpreted as medical advice. Investigational therapies discussed in this episode have not necessarily been established as safe or effective by regulatory authorities.

MAPS Chief Medical Officer Charlotte Kremer sits down with Dr. Bjorn Oddens, Senior Vice President, Value and Implementation at Merck, for a candid conversation on the career-defining moments, hard-won lessons, and mentors that shaped his path — plus his view on where Medical Affairs is headed over the next decade. About the Medical Affairs Professional Society (MAPS)The Medical Affairs Professional Society (MAPS) is the leading global authority and community for Medical Affairs professionals, uniting over 18,000 members across 400+ organizations in Pharmaceutical, Biotech, MedTech, and related industries. Founded in 2016, MAPS is a 501(c)(3) nonprofit dedicated to advancing careers and elevating the Medical Affairs profession worldwide. 

Dr. Santarvis Brown, educator, pastor, author, and Chief Education Officer at ProQ, joins Michael D. Levitt on the Breakfast Leadership Show for a powerful conversation about leading with purpose. With over 20 years in education and 15 years in pastoral ministry, Dr. Brown brings academic rigor, spiritual grounding, and practical business insight to every leadership conversation.The Leader You Have to Lead First: YourselfIn his book "Leading While Limping," Dr. Brown challenges leaders to confront their own "bang-ups and hang-ups" without filters or masks. When you avoid that internal reckoning, you risk inflicting your unresolved issues onto the people you lead. Authentic leadership begins with radical self-honesty. As Michael puts it, you will spend more time with yourself than with any other person on earth. Working through whatever you find within is not optional for any leader who wants to create lasting impact.Impact Over TitleDuring his tenure as the top education official for the Seminole Tribe of Florida's Department of Education, a young student wandered to the executive floor looking for homework help. Dr. Brown pulled up a chair and helped him with his reading. When the boy's mother arrived, the student looked at her and said simply, "He's a teacher." That moment crystallized the principle Dr. Brown carries everywhere: your title comes and goes, but your impact remains.The Story That Became a ChapterDr. Brown shares a defining story from "Leading While Limping." A university student he mentored went silent one evening, breaking from his usual enthusiastic greeting. Dr. Brown turned around in the parking lot, took the student to a nearby Denny's, and had a conversation about everything and nothing. At 1:30 a.m., the student sent an email with the subject line: "You saved my life." He had been on the verge of ending it rather than returning home without finishing his degree. Dr. Brown was on campus at 5:00 a.m. the next morning, and together they secured the funding needed to get him to graduation. Nearly 20 years later, that student still introduces Dr. Brown to everyone with the same words. The lesson: sometimes you are the aspirin to someone else's headache while carrying a migraine of your own.Human Connection Is Not OptionalLeaders who isolate themselves behind titles miss the very thing that makes people want to follow them. Genuine presence, curiosity, and interest in another person are not soft skills. They are the foundation of any leadership worth building.Growth as a Problem: The Chaos TaxProQ, founded on the book "Don't Walk Off a Cliff in Business" by Thomas McDonald, operates on a simple principle: predictable, scalable, reliable progress. Dr. Brown explains that not all growth is good growth. When growth outpaces process, businesses pay a chaos tax in inefficiency, burnout, and lost leadership bandwidth. ProQ helps organizations grow incrementally and intentionally so that progress becomes sustainable. As Dr. Brown puts it, businesses fail today not because they lack opportunity or know-how, but because they lack process.Connect with Dr. Santarvis BrownLearn more about ProQ at ProQSystems.com https://www.proqsystems.comConnect directly with Dr. Brown at TheLeadershipDoctorSB@gmail.com and subscribe to his YouTube channel, The Leadership Doctor SB (https://www.youtube.com/@TheLeadershipDoctorSB), where he diagnoses leadership challenges every week.Schedule Your Leadership DiagnosticVisit https://www.breakfastleadership.com/leadershipos to schedule a leadership diagnostic for your company today. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Independent Board Director and five-time public company CFO Alan Shaw returns to the show for an update on current biotech financing and the strategies needed to secure capital now. Allan explains how biotech investors price risk as the market opens back up, the importance of valuation discipline, and the financing choices that separate “available capital” from “accessible capital.” Allan also discusses the trade-offs inherent to different funding types.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. First, let's delve into the innovative work being done by Grove Biopharma. Founded in 2020 in Chicago, this company is at the forefront of developing polymer-peptide hybrids to target intracellular protein-protein interactions, areas traditionally deemed undruggable. These interactions are crucial regulatory components in numerous cellular processes and are implicated in diseases like cancer and neurodegenerative disorders. However, their smooth protein surfaces present a challenge for traditional small molecule drugs, which struggle to find suitable binding pockets. Similarly, biologics like antibodies and peptides, despite their high binding affinities, face difficulties penetrating cell membranes due to their size and instability. Grove Biopharma addresses these issues through its proprietary Bionics Biologics™ technology. Developed by Nathan Gianneschi at Northwestern University, this approach uses protein-like polymers to mimic proteins with enhanced stability and cellular penetration. These polymers, adorned with peptide branches via living polymerization, maintain peptide binding properties while overcoming previous limitations in drug delivery. This breakthrough has already shown promise in preclinical studies. A 2023 study in Science Advances revealed the efficacy of targeting membrane protein CD36 for treating macular degeneration in mice, while a 2024 study demonstrated PLPs' ability to penetrate neurons and target mitochondria in Huntington's disease models. Moreover, a 2026 Nature Communications publication introduced HYDRAC, a new PLP class capable of degrading MYC and KRAS proteins, reducing tumor growth in mice. Grove Biopharma's pipeline is robust, targeting key areas in cancer and neurodegeneration. Despite challenges typical of the biotech landscape—such as toxicity concerns during clinical trials and scalability issues—Grove's unique platform offers the flexibility needed to address multiple targets effectively. Shifting focus to industry-wide developments, recent advancements highlight significant strides in personalized medicine. Moderna and Merck's mRNA cancer vaccine has shown promising results in a phase 3 study, marking an important step forward for customized healthcare approaches based on genetic profiles. This not only offers hope for cancer treatment but also signifies a wider shift towards more tailored therapeutic strategies. Regulatory updates also play a critical role in shaping industry dynamics. The appointment of Dr. Angelo De Claro as chief of the FDA Oncology Center of Excellence is pivotal. His focus on modernizing regulatory practices aims to expedite drug approvals while ensuring that innovative treatments reach patients more swiftly. However, the FDA's decision to delay approval for Exelixis' tyrosine kinase inhibitor with Roche's Tecentriq underscores the complexities involved in novel therapies' assessments. On the geographical front, Singapore's launch of a biotech hub in Boston highlights the global nature of biotech development. This move strengthens historical ties and emphasizes international collaboration's importance in accelerating scientific research. In clinical trials, AbbVie's success with Qulipta (atogepant) for menstrual migraine prevention is noteworthy. It not only expands therapeutic options for women but also underscores a growing focus on gender-specific health issues within clinical research. Meanwhile, new RAS-targeting therapies continue to emerge as Revolution Medicines' Rasonque gains approval for advanced pancreatic cancer treatment—a significant milestone in addressing previously undruggable mutations. Industry dynamics are further illustrated by leadership changes at major firms like Takeda. The departure of long-time R&D chief Andy Plump often signals strategic shifts that could influence research priorities and corporate focus. Novartis recently faced setbacks with late-stage asset failures impacting its market position and raising investor concerns about its strategic direction concerning mergers and acquisitions. On a similar note, Takeda undergoes organizational changes amid potential strategic shifts following its CEO appointment—demonstrating volatility within companies striving for competitive advantage through effective leadership. Promising developments at the FDA include solidifying leadership with Karim Mikhail at CBER and Michael Davis at CDER—crucial appointments ensuring operational stability amidst past disruptions under former commissioner Marty Makary—and appointing Jared Seehafer as deputy commissioner focusing on AI integration into regulatory processes. Significant financial movements continue highlighting investor interest: Frazier adds over $1 billion targeting small-mid-sized biotech firms while Samsung Biologics secures manufacturing deals emphasizing strategic partnerships' importance globally. Scientific developments also reveal challenges; Silence Therapeutics maintains polycythemia vera leadership despite emerging hurdles while Novo Nordisk halts heart disease studies reflecting complexities validating interleukin-6 as therapeutic targets. AI integration gains momentum transforming operational efficiencies across various functions from R&D to human resources optimizing overall effectiveness within life sciences organizations—a trend poised to reshape people strategy profoundly impacting medical affairs evidenced evaluations enhancing decision-making processes ultimately improving patient outcomes significantly moving forward amidst this dynamic industry landscape filled with opportunities and risks requiring agility and forward-thinking strategies to capitalize on emerging scenarios efficiently and effectively ensuring continued success thriving amidst transformations occurring rapidly around us today, tomorrow, and beyond!Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the significant advancements and challenges that are shaping the future of drug development, regulatory landscapes, and industry innovations. Starting with a major milestone in personalized cancer therapy, the FDA has expanded Bayer's approval for Hyrnuo (zipalertinib) to include its use as a first-line treatment for HER2-mutant non-small cell lung cancer (NSCLC). This approval is based on promising Phase 1/2 clinical data, highlighting zipalertinib's role as a tyrosine kinase inhibitor targeting specific genetic mutations. This development is part of a broader trend towards precision medicine in oncology, allowing treatments to be specifically tailored to patients' genetic profiles. The potential impact on patient care is substantial, offering more effective treatment options for those with this particular HER2 mutation. In parallel, Johnson & Johnson's Imbruvica (ibrutinib) regimen has been endorsed by NICE for mantle cell lymphoma. These advancements represent a significant shift towards integrating precision medicine into oncology, aiming to improve outcomes by focusing on individual patient needs. On the business front, Samsung Biologics has secured a $262 million manufacturing deal with an unnamed European pharmaceutical company. This highlights an increasing demand for biologics manufacturing capabilities and reflects a growing reliance on contract development and manufacturing organizations (CDMOs) to meet complex therapeutic needs. Meanwhile, EMD Serono's acquisition of PostEra's AI-discovered fertility programs marks a pivotal move towards incorporating artificial intelligence in drug discovery, potentially revolutionizing women's health and fertility treatments. Clinical trial successes continue to drive momentum in the sector. AbbVie's Qulipta (atogepant) achieved its primary endpoint in a Phase 3 trial focused on menstrual migraines through CGRP receptor antagonism. This positions Qulipta as a promising new therapy within neurological disorders. Similarly, Rezera's Ruvonoflast met its primary endpoint in treating peripheral artery disease via NLRP3 inhibition, showcasing innovative anti-inflammatory approaches within cardiovascular medicine. Investment remains robust across the industry landscape. Frazier Life Sciences has successfully raised $1.1 billion to support small to mid-cap biotech companies, aiming to foster innovation and support emerging firms through critical phases of drug development. Additionally, CordenPharma's €80 million investment in enhancing aseptic fill-finish capacity illustrates strategic expansions within pharmaceutical manufacturing infrastructure. However, regulatory challenges persist. NICE's rejection of Gilead Sciences' lenacapavir due to cost concerns underscores ongoing debates around drug pricing and accessibility within healthcare systems. Furthermore, Biohaven Pharmaceuticals faces a partial clinical hold by the FDA on its epilepsy drug trial due to safety concerns. These instances highlight the rigorous scrutiny required throughout drug development processes. In response to these challenges, companies are increasingly adopting sophisticated strategies to navigate the evolving regulatory landscape. The "most favored nation" pricing policy in the U.S., designed to align domestic drug prices with those abroad, is prompting pharmaceutical firms to reassess their market strategies amid shifting economic conditions. On an optimistic note, Encoded Therapeutics has raised $275 million in Series F financing aimed at advancing gene therapies for conditions like Dravet syndrome. This substantial investment underscores confidence in gene therapy as a transformative approach for treating complex neurological and rare diseases. Finally, Ionis Pharmaceuticals achieved a breakthrough with its therapy approval for Alexander disease, illustrating the growing emphasis on targeting genetic disorders through precision medicine approaches. Such developments reflect both the dynamic nature of scientific innovation and the inherent challenges that accompany it. As these advancements unfold across various therapeutic areas and technological innovations continue to transform industry practices, it becomes increasingly clear that strategic planning and investment in research are crucial for translating scientific breakthroughs into tangible patient benefits. The ability of companies to innovate while ensuring compliance and economic viability will be pivotal as they strive to redefine treatment paradigms within this highly competitive sector. Thank you for joining us today on Pharma Daily. Stay tuned for more updates as we continue to bring you the latest insights from the ever-evolving pharmaceutical and biotech industries.Support the show

What does it take to crack the code of protein production and why do some proteins stubbornly refuse to cooperate, despite the best efforts of scientists and engineers? Biotech's ambitions are often limited not by vision, but by the real-world bottlenecks of host cell lines and the unpredictability of post-translational modifications.Nathan Lewis, GRA Eminent Scholar at the Center for Molecular Medicine, Complex Carbohydrate Research Center, and Department of Biochemistry and Molecular Biology at the University of Georgia, has made a career out of asking impossible questions about glycosylation, cell line selection, and the hidden machinery at work inside every productive cell. He's moved beyond academic curiosity—translating discoveries into applications and even launching a company, Augment Biologics, that's taking glycoengineering from theory to practice.Topics discussed:A proximity proteomics approach to identify supporting machinery for challenging-to-express proteins like rituximab (02:36)Findings from expressing the full human secretome in CHO cells, and the correlation between host cell gene expression and protein productivity (05:00)Clarifying when host cell characteristics matter more than the protein construct itself (05:46)Emerging evidence that protein sequence and structure influence glycosylation patterns (contrary to previous dogma) (06:49)Engineering point mutations to precisely tune glycan features for improved therapeutic efficacy (09:25)The vision and activities of Augment Biologics in custom glycosylation control for drug discovery (10:32)The importance and barriers to open data sharing in bioprocessing, and thoughts on overcoming them (11:11)The shifting landscape as technology advances and the need for high-quality, annotated data (13:54)If this got you thinking about the data already sitting in your freezer, and what it would take to actually use it, start here. These four conversations dig into AI-ready data, actionable omics, hybrid-model digital twins, and the cell-engineering biology underneath it all.Episodes 263 - 264: Why AI and Automation Tools Won't Deliver Until Your Lab's Data Is Connected with David HardyEpisodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist GernaeyEpisodes 169 - 170: Why Your DNA Is a Terrible Disease Predictor (And How Multi-Omics Changes Everything) with Mo JainEpisodes 77 - 78: Cell Factories Explained: How Synthetic Biology and AI Revolutionize Protein Production with Mauro TorresIf you'd rather follow the glycosylation thread, check Episodes 69 - 70: Glycoanalytics Explained with Róisín O'FlahertyConnect with Nathan Lewis:Website: www.lewislab.uga.edu LinkedIn: www.linkedin.com/in/nathanelewisFree 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it hereSupport the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Sandoz's recent move to invest $2.5 billion in creating a vertically integrated biosimilar manufacturing network is making waves across the industry. This significant investment underscores the growing importance of biosimilars as cost-effective alternatives to biologics. With plans to develop 100 biosimilars by 2040, Sandoz is strategically positioning itself to meet increasing global demand for affordable treatments. This initiative not only enhances their production capabilities but also aligns with the push from healthcare systems worldwide for more economical care options. The vertical integration model promises to streamline production, reduce supply chain issues, and maintain high-quality standards, reinforcing Sandoz's competitive position in the biosimilars market. Meanwhile, Amgen has achieved a noteworthy milestone with its drug Imdelltra (tarlatamab-dlle), which met its Phase 3 overall survival endpoint for extensive-stage small-cell lung cancer (SCLC) maintenance therapy. Imdelltra, a bispecific T-cell engager targeting DLL3, represents a novel approach in oncology, potentially setting a new standard of care for SCLC patients who have severely limited treatment options. The positive trial results could lead to regulatory approval, broadening access to this innovative therapy and potentially improving patient outcomes significantly. Regulatory stability is on the horizon with the FDA appointing permanent heads for its Center for Biologics Evaluation and Research (CBER) and Center for Drug Evaluation and Research (CDER). This leadership continuity is crucial as it supports the agency's ongoing restructuring efforts aimed at enhancing efficiency and oversight. Stable leadership within these centers ensures rigorous drug evaluation processes continue, which is critical for timely approvals and has a direct impact on drug developers' strategic planning and market entry timelines. Clinical trials continue to yield varied results, showcasing the inherent uncertainties in drug development. AstraZeneca's Tozorakimab showed promise with approximately a 30% reduction in exacerbations in Phase 3 trials for chronic obstructive pulmonary disease (COPD), hinting at improved management of respiratory diseases through targeted monoclonal antibody therapies. Conversely, challenges persist as Evommune's Evo756 did not meet its Phase 2b trial expectations for atopic dermatitis, and Tyra Biosciences' Dabogratinib fell short in non-muscle invasive bladder cancer trials—highlighting the unpredictable nature of clinical research. Investment flows into biopharmaceuticals remain robust, with Encoded Therapeutics raising $275 million to advance its gene therapy program for Dravet syndrome. Similarly, Luma Group has secured $410 million for ventures focusing on ophthalmology and cellular rejuvenation technologies. Such investments reflect strong confidence in gene and cell therapies' transformative potential on patient care. On the mergers and acquisitions front, Sernova Biotherapeutics' merger with Seraxis to form Betanova Biotherapeutics exemplifies how companies are consolidating expertise to enhance R&D capabilities and expand their market reach, particularly in cell therapy solutions for diabetes management. These strategic consolidations indicate ongoing efforts to leverage synergies that could redefine therapeutic landscapes. The biopharmaceutical sector is also seeing shifts due to ongoing geopolitical tensions between the U.S. and China, pushing companies to seek investment opportunities outside China. This diversification strategy aims to mitigate geopolitical risks while continuing global innovation efforts. In obesity treatment research, partnerships like those between GemPharmaTech signal new frontiers beyond GLP-1 receptor agonists. These collaborations highlight an industry commitment to tackling global health challenges with innovative therapies that prioritize efficacy and safety. These developments collectively paint a picture of a dynamic industry marked by scientific breakthroughs, strategic investments, regulatory evolution, and significant challenges in clinical trials. As these sectors evolve, they promise exciting advancements that could profoundly redefine global healthcare paradigms. The focus remains on overcoming therapeutic barriers through sustained research efforts and innovative approaches—a testament to the industry's relentless pursuit of improving patient care outcomes worldwide.Support the show

AZ TRT 2.0 – Best of Cybersecurity from Business to Government AZ TRT S07 EP14 (296) 9-6-2026   What We Learned This Week Cyber and CIO mgmt Common Cyber Issues TRM Labs on security ACTRA - Cyber threats affect everyone from Gov't to business to private & growing Clips from past shows focusing on Cybersecurity and threats to both business and Government. .     Seg. 1 Clips from Related Shows: Cybersecurity, Disruption, Blockchain & Terrorism w Ari Redbord of TRM Labs - BRT S02 EP31 (78) 8-1-2021     What We Learned This Week Cybersecurity is extremely important industry for national security TRM Labs startup in cyber-security, monitors blockchain OFAC - Gov't administers economic and trade sanctions Ransomeware – specific breach, takeover of a computer system, holds data hostage Programatic Money Laundering – bad guys create new addresses, create 'shell' companies   Guest: Ari Redbord, Head of Legal and Government Affairs w/ TRM Labs https://www.linkedin.com/in/ari-redbord-4054381b4/ https://www.trmlabs.com/post/trm-labs-appoints-ari-redbord-as-head-of-legal-government-affairs   Ari is formerly a US Attorney, and worked in the Treasury Department, now advises the Government on cybersecurity, and Blockchain. Cybersecurity is a fast growing and extremely important industry for national security, and corporate interests. There are Nation States acting as bad players in the cyber realm and targeting the US Government and US business. We discuss the advancements in technology on cyber crime, blockchain, crypto, and online fraud. How is the FBI dealing with Ransomware, and other cyber attacks on prime targets like the Colonial Pipeline, or other big corps. What Regulations are coming in banking, and Fintech, with KYC (Know Your Customer), plus the big banks like JP Morgan Chase and Goldman are on board.  What the blockchain ledger can help solve in security, to monitor criminal activity in real time with the help of crypto exchanges like Coinbase.  Lastly, what TRM Labs does for clients, how they advise, operate, and who they work with.   Full Show: HERE     Phishing, Malware & Cybersecurity - Try Not to Get Pwned - BRT S02 EP47 (94) 11-21-2021   What We Learned This Week:   Have I been Pwned? Means have I been breached / hacked – did someone hack my email or website Phishing – most common type of email threat, like when you receive a strange email with a link – Do Not Open – DELETE (and alert other office staff of the email) Ramsonware – hack your website, or data – hold it hostage for an extortion 'ransom' payment Dark Web – where stolen data, & info is being bought & sold VPN Connections – direct and secure   Guests: Vince Matteo, Seven Layer Networks, Inc. https://sevenlayers.com/ Vince Matteo is a certified penetration tester, a security researcher, and a senior consultant at Seven Layers (.com) where he focuses on securing small businesses.  Vince is the author of "Hacking 101 – A Beginner's Guide to Penetration Testing", he's a bug bounty hunter with 17 published critical vulnerabilities, and he's presented talks on offensive hacking at security conferences -- most recently GrrCON in Grand Rapids, MI and BSides in College Station, TX.  Outside of work, Vince is an accomplished endurance athlete, an Ironman age group champion, and in his spare time, you can find him in the desert -- training for the next hundred-mile ultramarathon.    Full Show: HERE     Seg. 2 Cybersecurity Response Plan w/ Frank Grimmelmann of ACTRA   - AZ TRT S06 EP03 (264) 2-9-2025                 What We Learned This Week ACTRA Arizona Cyber Threat Response Alliance Cyber threats affect everyone from Gov't to business to private and growing Companies need to be responsive with speed to be effective + share information of attacks ACTRA has members from both government and private sector ACTRA helped create a state cybersecurity response model that other states can use     Guest: Frank Grimmelmann https://www.actraaz.org/actra/leadership President & CEO/Intelligence Liaison Officer   Mr. Grimmelmann also serves as Co-Chair (together with Arizona's Chief Information Security Officer) for the Arizona Cybersecurity Team ('ACT'), created through the Governor's Executive Order signed in March 2018. He also serves as a Founding Member of the National Leadership Group for the Information Sharing & Analysis Organization Standards Organization ('ISAO SO') at the University of Texas San Antonio (UTSA), created under the President's Executive Order 13691 in February 2015. As ACTRA's leader, Mr. Grimmelmann was invited as the first private sector representative in the Arizona Counter Terrorism Information Center (ACTIC) and served as its first private sector Executive Board representative from 2014-2019. He presently acts as ACTRA's designated private sector liaison to ACTRA's Key Agency and other non-Member Stakeholders.    Full Show: HERE   Seg. 3   Cybersecurity & Compliance w/ Paige Hanson of Secure Labs - AZ TRT S06 EP15 (277) 8-17-2025       What We Learned This Week: A cybersecurity breach can cost more than just data—it can damage infrastructure and destroy client confidence. Even smaller companies (50–100 employees) need structured safeguards, compliance, and often outside MSSPs to stay secure. Secure Labs provides a roadmap for companies to meet regulatory standards like HIPAA, ISO 27001, and SOC 2, helping them win bigger clients. AI-driven threats like voice cloning and deepfakes make personal and business digital security more important than ever. Compliance isn't cheap—outside audits can run $5,000–$50,000 annually, while Big Four audits may exceed $100,000.       Guest: Paige Hanson, Co-Founder of Secure Labs   LinkedIn: https://www.linkedin.com/in/hello-paige-hanson Founder of SecureLabs | Helping businesses meet their security compliance standards | Fractional GRC | 

Who does the person at the top turn to when they need advice?In this episode, host Elaine Hamm, PhD, sits down with Rod Beeler, Executive Partner at Magellan Executive Partners, to explore the value of executive coaching for entrepreneurs, startup founders, and business leaders. Drawing on more than 30 years of global leadership experience, Rod shares how an outside perspective can help executives tackle immediate challenges while developing the skills and long-term vision they need to become more effective leaders.In this episode, you'll discover:Why having a confidential, trusted outside perspective can be especially valuable for startup founders and executives.How effective executive coaching goes beyond a one-size-fits-all formula to address each leader's individual challenges, goals, and development.How coaching can help leaders navigate everything from team dynamics and conflict to boards, investors, long-term strategy, and the isolation that can accompany leadership.Tune in to discover why even the person leading the team can benefit from having a coach in their corner.Links:Connect with Rod Beeler and learn about Magellan Executive Partners.Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine.Check out Caterpillar and the Latitude podcast.Connect with Ian McLachlan, BIO from the BAYOU producer. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we unveil a series of transformative strides in drug approvals, clinical trials, and regulatory landscapes that are reshaping the future of patient care. AstraZeneca's camizestrant, now branded as Etcamah, has received FDA approval for treating ESR1-mutated hormone receptor-positive, HER2-negative advanced breast cancer. This approval is a testament to the potential of selective estrogen receptor degraders (SERDs) in oncology. The Phase 3 trial results highlight camizestrant's efficacy when combined with CDK4/6 inhibitors, offering a tailored therapeutic strategy for patients with ESR1 mutations. Such advancements in personalized oncology are steering the industry toward more precise treatment paradigms. Complementing this approval, Guardant Health's Guardant360 CDx has been sanctioned as a companion diagnostic tool for camizestrant. The liquid biopsy-based method precisely identifies ESR1 mutations, underscoring the growing reliance on precision diagnostics in cancer management. As precision medicine continues to evolve, integrating diagnostics with therapeutics becomes crucial in achieving optimal patient outcomes. Bristol Myers Squibb has made headlines with its CAR-T cell therapy, arlocabtagene autoleucel, showing efficacy in its Phase 3 trial for GPRC5D-targeted relapsed or refractory multiple myeloma. This advancement reflects the burgeoning application of cell-based treatments in hematological malignancies and signals a shift towards personalized immunotherapy strategies promising improved patient outcomes. On a related note, Brainchild Bio's significant $116 million fundraising initiative aims to advance CAR-T therapies tailored for childhood brain cancers. This development highlights the potential of CAR-T technology beyond hematologic cancers and indicates an intensified focus on pediatric oncology therapeutics. In regulatory news, Shionogi's cefiderocol has gained approval from Australia's Therapeutic Goods Administration (TGA) for combating carbapenem-resistant gram-negative bacterial infections. Cefiderocol addresses critical needs in combating multidrug-resistant pathogens, particularly in urinary tract infections, and highlights ongoing global efforts to tackle antimicrobial resistance. Clinical trials continue to yield promising outcomes. Pharvaris' deucrictibant showcased positive results in its Phase 3 trial for hereditary angioedema by effectively targeting the bradykinin B2 receptor. Novo Nordisk's semaglutide (Wegovy) demonstrated remarkable efficacy in reducing obesity among children during its Phase 3 trials. These results emphasize continued innovation in treating metabolic disorders and rare diseases by leveraging small molecule therapeutics and receptor modulators. Not all developments have been positive. Novartis and Ionis Pharmaceuticals faced setbacks with pelacarsen failing to meet endpoints in a Phase 3 trial aimed at reducing major cardiovascular events despite lowering lipoprotein(a). This underscores the challenges of translating promising biomarkers into effective therapeutic interventions. Regulatory challenges were also observed as American Regent recalled batches of epinephrine due to contamination issues, and Boston Scientific recalled spinal cord implants linked to serious injuries. These instances underscore the importance of stringent quality control and regulatory compliance to ensure patient safety. Meanwhile, Amgen's DLL3-targeted therapy, Imdelltra, achieved an overall survival win in a first-line setting for small cell lung cancer (SCLC), although specific numerical results were not disclosed. This bispecific antibody could set a new standard for early intervention in SCLC, emphasizing the potential of targeted therapies in improving survival rates for aggressive cancers. In other advancements, Roche continues to dominate neurology with top positions in corporate reputation rankings within this therapeutic area. This accolade reflects Roche's commitment to innovation and patient-centric approaches to managing neurological disorders. As these developments unfold across various domains of pharmaceutical innovation and regulation, they collectively signal a dynamic era for the industry marked by rapid scientific progress and evolving treatment strategies. The implications are profound, offering potential improvements in patient outcomes through more targeted therapies while highlighting challenges such as clinical trial failures that necessitate continued diligence in drug development strategies. As these trends unfold, they hold promise for significant advancements in treatment efficacy and safety across various therapeutic areas. Thank you for tuning into Pharma Daily. Stay informed about the latest industry developments as we continue to explore the dynamic landscape of pharmaceutical innovations together.Support the show

Alice Han and James Kynge look ahead to Trump and Xi's September 24 meeting in Washington, set against a busy stretch of Xi diplomacy, from the SCO summit to a first-ever trip to India, plus talk of a possible Trump-Putin-Xi trilateral in November. They dig into how trade, rare earths, and soybean purchases are shifting the leverage between the two powers, and whether the fight over AI dominance deserves more attention than the trade deficit. Then: Ruby Wang, author of China Cure: The Rise of a Biotech, AI Medicine and Global Health Superpower, joins to unpack China's rapid rise in pharmaceuticals — from faster, cheaper clinical trials to a wave of global licensing deals now worth tens of billions of dollars. She explains what changed since China was a clear follower in the market as recently as 2010, and what it means for U.S. pharma competitiveness. Subscribe to China Decode on Substack for weekly analysis, livestreams, and deep dives into the biggest story shaping the global economy: chinadecode.profgmedia.com. Learn more about your ad choices. Visit podcastchoices.com/adchoices

P.M. Edition for Sept. 8. OpenAI says it's cracked the Navier-Stokes problem, one of the seven Millennium Prize Problems that are the deepest and most difficult unresolved questions in mathematics. WSJ Science of Success columnist Ben Cohen explains why labs like OpenAI are competing—and spending millions—for such breakthroughs. Plus, a dozen nations are imposing new trade restrictions on Israel over the expansion of settlements in the West Bank. And Smithsonian Secretary Lonnie Bunch III, the first African-American and the first historian to lead the institution, is stepping down after more than a year of tension with President Trump. Alex Ossola hosts. Sign up for the WSJ's free What's News newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Jeremy Heffner, MD, FACS is a board-certified trauma surgeon, former Chair of Surgery at Lima Memorial Health System, and cofounder of Surgery Unified, one of the largest physician-led communities in surgery. His perspective carries weight because he has spent decades inside operating rooms, hospital leadership, physician culture, and the growing collision between medicine and corporate healthcare. He grew up in a blue-collar Ohio family of firefighters, railroad workers, police officers, and tradespeople. Medicine represented something rare: a career that combined service, stability, and purpose. He pursued engineering, earned his medical degree, completed trauma surgery fellowship training at the University of Michigan, and entered a profession that taught physicians to sacrifice themselves for patients.Then the rules changed.This conversation traces the gap between the medicine physicians were trained to practice and the healthcare industry that emerged around them. Administrative burden expanded. Insurance companies gained influence over treatment decisions. Prior authorization became routine. Hospital systems consolidated. Physicians retained responsibility for outcomes while losing authority over the conditions required to achieve them.Heffner describes watching colleagues struggle with burnout, moral injury, PTSD, and growing frustration with a system that increasingly inserts business incentives between clinicians and patients. He explains why younger physicians are entering medicine with a level of visibility that previous generations never had. They see the paperwork, the denials, the loss of autonomy, and the personal cost before they ever finish training.The discussion moves beyond physician dissatisfaction and into the broader consequences for patients. When insurers delay care, hospitals absorb costs, clinicians absorb stress, and patients absorb uncertainty. The financial incentives remain intact while trust erodes across every level of the healthcare system.At its core, this episode examines what happens when a profession built around service finds itself operating inside an industry built around extraction. The result affects physicians, nurses, caregivers, and every patient forced to navigate the consequences.RELATED LINKSJeremy Heffner⁠Surgery Unified⁠SurgeOn⁠University of Michigan Department of Surgery⁠KevinMD⁠Suck It Up Buttercup⁠FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In today's episode, we're diving into a series of breakthroughs and significant updates that are shaping the landscape of medicine and treatment. Let's start with a remarkable development in the realm of personalized medicine. Researchers have announced a breakthrough in gene-editing technology that holds promise for treating a range of genetic disorders. This new technique, which builds upon CRISPR technology, allows for more precise editing of DNA, minimizing off-target effects that have been a concern in earlier methods. By improving the accuracy of gene editing, this advancement could potentially pave the way for safer and more effective therapies for conditions like cystic fibrosis and sickle cell anemia. The significance of this development cannot be understated, as it represents another step forward in the quest to tailor medical treatments to individual patients' genetic profiles. Moving on to regulatory news, the FDA has granted accelerated approval to a new therapy for a rare form of cancer. This drug, developed by a leading biotech firm, targets a specific mutation found in certain types of tumors. The approval was based on promising clinical trial results showing significant tumor shrinkage in patients who had exhausted other treatment options. Accelerated approval is crucial as it allows patients earlier access to potentially life-saving treatments while further confirmatory trials are conducted. This decision underscores the agency's commitment to supporting innovation in oncology and addressing unmet medical needs. In another significant update, a major pharmaceutical company has reported positive phase 3 trial results for its new Alzheimer's drug. This medication aims to slow cognitive decline by targeting amyloid plaques in the brain, which are believed to play a role in the progression of Alzheimer's disease. The trial demonstrated statistically significant improvements in cognitive function among participants receiving the treatment compared to those on placebo. These findings could be transformative for Alzheimer's patients and their families, offering hope where few treatment options exist today. If approved, this drug could become one of the first disease-modifying therapies for Alzheimer's, marking a significant milestone in neurological research. Shifting our focus to vaccine development, scientists have made progress on a universal flu vaccine. This innovative approach seeks to provide broad protection against multiple strains of influenza with a single shot. By targeting conserved elements of the virus that do not change from year to year, this vaccine could potentially eliminate the need for annual flu shots. Early-stage trials have shown promising immune responses, and researchers are optimistic about advancing to larger-scale studies. The development of such a vaccine would represent a major leap forward in public health, reducing the burden of seasonal flu outbreaks worldwide. Turning our attention to industry trends, there is growing interest in artificial intelligence and machine learning applications within drug discovery. A recent report highlights how AI is being used to predict drug-target interactions and streamline clinical trial design. By leveraging large datasets and computational power, AI can identify potential drug candidates more efficiently than traditional methods. This technology is revolutionizing research and development pipelines by accelerating timelines and reducing costs, ultimately leading to quicker patient access to new therapies. As more companies invest in AI-driven approaches, it is anticipated that these technologies will become integral components of pharmaceutical innovation. Lastly, an update on sustainability within the industry: several companies are making strides toward reducing their environmental footprint through green chemistry initiatives and sustainable manufacturing practices. These efforts aim to minimize waste and energy consumption while ensuring safe production processes. As environmental concerns become increasingly prominent, adopting sustainable practices is not only socially responsible but also aligns with consumer expectations and regulatory requirements. The movement towards sustainability within pharma reflects broader global trends prioritizing eco-friendly innovations across industries. That concludes today's episode of Pharma Daily. Thank you for tuning in to stay informed about the latest advancements and insights shaping healthcare's future. Be sure to join us next time as we continue to explore groundbreaking developments across the pharmaceutical landscape. Until then, stay curious and keep pushing forward in your pursuit of knowledge and innovation!Support the show

The AI infrastructure boom is running into a growing obstacle: communities and regulators are pushing back against massive data center projects. Simon and Dan look at why opposition to new data centers is accelerating, particularly around electricity demand, utility costs, water usage and the strain these projects can put on existing infrastructure. They also discuss what delays could mean for the AI buildout, which parts of the ecosystem could benefit from constrained computing capacity, and why Alberta is emerging as an important battleground for new projects. Then, Simon follows up on last week’s Royalty Pharma deep dive by looking at the different ways investors can gain exposure to pharmaceuticals and biotech. From diversified ETFs to established drugmakers, higher-risk biotech companies and the royalty model, they break down the trade-offs between diversification, upside potential and clinical-development risk. They also discuss why seemingly “safe” pharmaceutical giants can still carry significant concentration risk, how AI could reshape drug development, and why healthcare may be one of the more overlooked ways to invest in the AI theme. Stocks/ETFs discussed: RPRX, MRNA, MRK, JNJ, ABBV, LLY, VRTX, REGN, AMGN, GILD, ISRG, SHOP, HUT, SEI, TT, IXJ, ZHU.TO, XPH, IHE, IBB, XBI. Subscribe to our Our New Youtube Channel! Check out our portfolio by going to Jointci.com Our Website Our New Youtube Channel! Canadian Investor Podcast Network Twitter: @cdn_investing Simon’s twitter: @Fiat_Iceberg Braden’s twitter: @BradoCapital Dan’s Twitter: @stocktrades_ca Want to learn more about Real Estate Investing? Check out the Canadian Real Estate Investor Podcast! Apple Podcast - The Canadian Real Estate Investor Spotify - The Canadian Real Estate Investor Web player - The Canadian Real Estate Investor Asset Allocation ETFs | BMO Global Asset Management Sign up for Fiscal.ai for free to get easy access to global stock coverage and powerful AI investing tools. Register for EQ Bank, the seamless digital banking experience with better rates and no nonsense.See omnystudio.com/listener for privacy information.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, David Craig, Cofounder, President, and CEO at Sarcomatrix, explains why the old biotech playbook breaks down in today's funding environment and what it takes to build a lean virtual drug development company without institutional financing. Craig describes practical financing paths, hard truths about costs, and the tradeoffs that make a rare disease program investable through alternative fundraising strategies. He also shares what can and cannot be outsourced, and how regulatory sequencing shapes financial planning and timelines. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

What if the biggest barrier to medtech innovation isn't the technology, buti fear? In this episode, Merom Klein explores how entrepreneurs can recognize hesitation, build trust, and move investors, customers, and teams from “wait and see” to active champions of innovation. From raising capital to changing the standard of care, Merom shares practical insights on building courage, understanding incentives, and creating the conditions for meaningful adoption. Tune in for a conversation about the human side of medtech innovation and what it really takes to change the game.Merom Klein LinkedInCourage Growth Partners LinkedIn Project Medtech Podcast Episode 249"Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust" by Jeremy M. Levin "Leadership the Hard Way" by Dov Frohman and Robert Howard "Start-Up Nation: The Story of Israel's Economic Miracle" by Daniel Senor and Saul Singer Duane Mancini LinkedInProject Medtech WebsiteProject Medtech LinkedInThank you to our sponsors: Ward Law, Wheelhouse DMG, and JumpStart Inc.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of pivotal advances and industry dynamics that are shaping the future of healthcare. The U.S. Food and Drug Administration has recently granted approval to Ionis Pharmaceuticals' Zanvastro, a breakthrough in treating Alexander disease. This condition, a rare neurodegenerative disorder caused by mutations in the glial fibrillary acidic protein gene, has historically posed significant treatment challenges. Zanvastro, an antisense oligonucleotide therapy, is notable for being the first of its kind to target this protein, marking a monumental step in precision medicine. The success of this therapy not only opens new avenues for treating Alexander disease but also highlights the potential of antisense technologies to address other rare genetic disorders. Ionis Pharmaceuticals is poised to further explore this innovative therapeutic approach in other neurodegenerative conditions like Angelman syndrome, reinforcing their leadership in targeting rare genetic diseases at the molecular level. Meanwhile, strategic partnerships continue to transform the metabolic disease treatment landscape. The Menarini Group's partnership with Gan & Lee Pharmaceuticals aims to bring the GLP-1 receptor agonist Bofanglutide to European markets. This collaboration underscores the growing emphasis on GLP-1 therapies for managing type 2 diabetes and obesity. With an investment of $72 million upfront and potential milestone payments reaching $771 million, this partnership illustrates the strategic importance of cross-border collaborations in accelerating drug availability and leveraging regional expertise. In parallel, Argo Biopharma has announced promising phase 2 results for its small interfering RNA therapy targeting plasma prekallikrein in hereditary angioedema. This innovative approach offers a prophylactic treatment option for a disease characterized by severe swelling attacks. By harnessing RNA interference mechanisms, Argo Biopharma joins a broader movement within biotech towards gene-silencing technologies that tackle previously challenging conditions. Further emphasizing innovation, Superluminal Medicines has raised $60 million to advance its AI-discovered MC4R-targeting drug for rare obesity conditions. This initiative highlights the transformative potential of artificial intelligence in drug discovery, enabling rapid identification of therapeutic candidates by analyzing extensive datasets and predicting molecular interactions. The focus on rare forms of obesity reflects a broader trend toward personalized medicine, where treatments are increasingly tailored to specific genetic profiles. Regulatory developments also feature prominently with Liquidia Corporation receiving FDA fast track designation for Yutrepia, an inhaled small molecule aimed at treating systemic sclerosis-related Raynaud's phenomenon. This designation will expedite the development and review process for Yutrepia, facilitating quicker access to this potentially life-enhancing treatment for those suffering from autoimmune complications. However, challenges persist within the industry. The FDA issued a warning letter to Fresenius Medical Care over deficiencies related to complaint handling and contamination inspections for sterile injectable products. This action underscores ongoing concerns regarding compliance with safety standards and highlights the critical need for rigorous quality control mechanisms to ensure patient safety. In exploring new therapeutic modalities, psilocybin has shown promise in managing neuropathic pain through preclinical studies. These findings add to the growing body of evidence supporting psychedelics' potential benefits beyond mental health applications, opening new avenues for pain management therapies that could revolutionize treatment protocols. The competitive landscape in weight management sees significant movement with Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo vying for dominance in oral GLP-1 receptor agonists. As companies race to develop more patient-friendly formulations, these innovations promise to significantly boost adherence and outcomes in obesity management. Lastly, industry trends reveal an evolving marketing landscape where social media collaborations and strategic partnerships are becoming central to engaging patients and advocating medical conditions. For example, Novartis' partnership with a British Olympian aims to enhance multiple sclerosis advocacy by leveraging influential platforms for patient education and empowerment. These developments paint a picture of a dynamic pharmaceutical and biotech sector characterized by scientific innovation, strategic partnerships, regulatory vigilance, and data-driven approaches. As companies continue to navigate these complexities, their ability to leverage cutting-edge technologies and foster global collaborations will be crucial in delivering transformative health solutions. The industry's focus on precision medicine and novel therapeutic modalities promises significant advancements in patient care and disease management in the years ahead. Thank you for joining us at Pharma Daily—your source for the latest news shaping the world of pharmaceuticals and biotechnology.Support the show

Episode 187 of the Tap Room Podcast — host Mike visits Rio Hondo College and La Bodega to talk brewing with Abraham Ricardo (owner/head brewer), cellarman/brewer Matt Godinez, and five students from the biotech & brewing class: Steven Olivarez, Anthony Gomez, Carlo Mejia, Mauricio Ramos and Nicole Campos. Topics include the course structure (history, beer styles, malt/hops/yeast fundamentals), fermentation science, sensory tasting, hands-on brew days, sanitation, and the realities of working in craft beer. Students share what surprised them, favorite styles, and why a strong foundation matters. Listen for practical advice for aspiring brewers, stories about transitioning careers into the industry, and why passion and experimentation drive craft beer culture.

This interview is disseminated on behalf of Theralase Technologies Inc.Theralase Technologies Inc. (TSXV: TLT | OTCQB: TLTFF) Chairman, President, and CEO Roger Dumoulin-White, B.Sc, P. Eng. discusses the company's clinical-stage cancer treatment technology and its development for patients with BCG-unresponsive non-muscle invasive bladder cancer. The interview covers interim Phase II clinical study results for Ruvidar®, including response durability and safety, as well as the potential advantages of Theralase's drug and proprietary light activation system.Learn more: https://theralase.com/Watch the full YouTube interview here: https://www.youtube.com/watch?v=sb-_w3PoR_kAnd follow us to stay updated: https://www.youtube.com/@stockstowatchofficial 

In this episode of the Limitless Podcast, Dr. Matthew Preston and Dr. Thaon Simms welcome back Ryan Strachan for a wide-ranging conversation on investing, Jamaica's energy future, infrastructure, the Jamaica Stock Exchange, and the forces that could reshape the Jamaican economy.⚡ A major focus is the future of JPS and Jamaica's electricity sector. Ryan explores what the upcoming changes could mean for renewable energy, battery storage, electricity prices, manufacturing, household expenses, and economic growth. Could cheaper energy unlock an entirely new phase for Jamaican businesses and investors?

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of fascinating updates that are shaping the future of medicine and patient care. First on our agenda is uniQure's ambitious step toward accelerated U.S. marketing approval for AMT-130, a gene therapy targeting Huntington's disease. This move signifies a potential breakthrough in treating rare neurological disorders with genetic roots. The approval of AMT-130 would highlight gene therapy's transformative power, not just for Huntington's disease but also for a broader range of genetic conditions, offering hope to patients where traditional treatments have fallen short. In the realm of oncology, Summit Therapeutics, in collaboration with Akeso, has reported that their bispecific antibody ivonescimab has surpassed Merck's Keytruda in a Phase 3 trial for non-small cell lung cancer. The trial revealed superior overall survival and progression-free survival rates, marking a significant milestone in cancer treatment. Bispecific antibodies like ivonescimab open new avenues for targeting multiple pathways simultaneously, potentially leading to more effective therapies with reduced side effects. Collaboration continues to be a pivotal strategy in drug development. GSK and Hutchmed have formed a licensing agreement for HMPL-A830, an innovative cancer therapy. This partnership involves an upfront payment of $110 million, with the potential to reach $1.3 billion based on performance milestones. Such alliances highlight the importance of strategic partnerships in accelerating therapeutic advancements and expanding the arsenal of available cancer treatments. Moving to regulatory milestones, Samsung Bioepis has secured approval in Japan for its biosimilar ustekinumab, aimed at treating moderate-to-severe Crohn's disease by targeting IL-12/IL-23 pathways. This approval is part of a larger trend towards biosimilars as cost-effective alternatives to biologics, increasing access to essential treatments for autoimmune diseases. In cardiovascular health, Everest Medicines has received China NMPA approval for Cardamyst (etripamil), a self-administered nasal spray for paroxysmal supraventricular tachycardia. The approval underscores innovations in patient-centric drug delivery systems that offer easier administration methods and empower patients to manage their conditions effectively. On the business front, Fortrea has acquired Worldwide Clinical Trials' early-phase division for $45 million. This acquisition aims to bolster Fortrea's clinical research organization platform, reflecting the growing demand for comprehensive clinical pharmacology services that can accelerate drug development timelines. Meanwhile, Pfizer's divestment of its Seagen antibody-drug conjugate PF-08046031 to Medicus Pharma in a deal exceeding $1 billion exemplifies strategic realignments within large pharmaceutical companies. These transactions allow companies to streamline operations and focus on core therapeutic areas where they can make the most impact. Research advancements are also making headlines as Revolution Medicines reports promising Phase 1/2 data for Rasonque (daraxonrasib) in NSCLC patients with KRAS mutations. KRAS has been notoriously difficult to target, so these findings highlight Rasonque's potential as a breakthrough small molecule therapy addressing critical needs in oncology. Despite these strides forward, challenges remain evident. Ultragenyx's GTX-102 did not meet primary or secondary endpoints in its Phase 3 Angelman syndrome study. This setback highlights the complexities involved in developing effective treatments for rare neurological conditions and underscores the inherent risks in high-stakes clinical trials. Turning our attention back to regulatory dynamics, FDA deliberations over Replimune's melanoma treatment revealed nuanced decision-making processes balancing clinical evaluation with strategic considerations. Even amidst internal disagreements, FDA leadership endorsed an accelerated nod for Replimune's therapy—an illustration of how complex these processes can be. In terms of funding innovation, ARPA-H's substantial $125 million investment into personalized RNA-based drug production reflects a commitment to advancing RNA therapeutics despite recent challenges. The initiative could become a catalyst for new approaches in personalized medicine by leveraging RNA technologies to tailor treatments more precisely to individual profiles. Additionally, Roche is making headway in obesity treatment with its UCN2 analog, which shows promise in reducing weight without sacrificing lean muscle mass—an essential factor given obesity's global health implications. This development may introduce new mechanisms of action that could revolutionize existing therapies by overcoming metabolic challenges inherent in obesity treatment. Overall, these developments underscore a dynamic period within the pharmaceutical and biotech sectors characterized by rapid scientific progress and strategic realignments responding to evolving market demands. As companies navigate these changes, their ability to leverage new technologies and refine their strategic focus will be crucial in maintaining competitive advantage and driving future growth—all while aiming to improve patient outcomes globally.Support the show

In 1971, the National Cancer Act transformed cancer into a national research priority. More than 50 years later, the next frontier is no longer defined solely by scientific discovery, but by how quickly knowledge, lived experience, and patient voices can reshape healthcare itself.The concluding chapter of The Cancer Mavericks: A History of Survivorship explores how the cancer advocacy movement continues to evolve in an era of digital communities, social media, precision medicine, and grassroots activism. Building on the work of pioneers such as Mary Lasker, Rose Kushner, and the generations of survivors who followed, today's advocates are expanding the movement beyond awareness to demand health equity, trusted information, patient-centered research, and meaningful representation in healthcare decision-making.The episode examines how technology has transformed advocacy from local support groups into global communities capable of organizing in real time. Researchers, policymakers, nonprofit leaders, and survivors reflect on the growing influence of digital storytelling, online education, and peer-to-peer networks that connect patients across diagnoses, generations, and geographic boundaries. At the same time, they acknowledge new responsibilities: ensuring accurate medical information, combating misinformation, protecting trust, and keeping patients at the center of innovation.The story also looks ahead to the next generation of advocates. Young leaders are applying lessons learned from decades of cancer activism while drawing inspiration from broader movements for social justice, public health, and community organizing. Their work reflects a simple but enduring truth: meaningful change rarely begins inside institutions. It begins when ordinary people refuse to accept that the system cannot improve.Cancer survivorship has never been a finished story. Every generation inherits the progress achieved by those who came before while confronting challenges uniquely its own. The future of survivorship will be shaped not only by scientific breakthroughs, but by those willing to listen, organize, educate, and ensure that every patient's voice helps define what comes next.RELATED LINKSNational Cancer Institute⁠Cancer Moonshot⁠Centers for Disease Control and Prevention | Division of Cancer Prevention and Control⁠HopeLab⁠Tigerlily Foundation⁠Stupid Cancer⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Forget nonfarms — the options market has plenty of other things to keep traders busy. On this episode of The Option Block, Mark Longo, Uncle Mike Tosaw and Henry "The Flowmaster" Schwartz from Cboe break down a surprisingly strong market rally heading into the jobs report, the latest options volume trends, and some unusual activity lighting up the tape. The crew digs into eye-catching options flow in biotech name Alumis (ALMS) and drone maker Draganfly (DPRO), including some intriguing call activity as both names attract attention. They also examine unusual action in Element Solutions (ESI). Plus, we discuss the latest action in VIX, SPY, IWM and QQQ, a red-hot day for names including Robinhood, Palantir, Tesla and NVIDIA, the continued evolution of binary options and prediction markets, and whether unusually favorable options skew is creating opportunities for investors to hedge some high-flying stocks.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into groundbreaking scientific advancements, crucial regulatory updates, and strategic industry movements that are shaping the future of patient care and drug development. AstraZeneca, in collaboration with Daiichi Sankyo, has achieved a significant milestone with their antibody-drug conjugate, Enhertu, combined with Roche's Perjeta. This combination therapy has recently secured European Union approval for first-line treatment of HER2-positive metastatic breast cancer. The approval highlights the transformative potential of antibody-drug conjugates in treating aggressive breast cancer subtypes. Enhertu targets HER2-positive tumors by delivering cytotoxic agents directly to the cancer cells, thereby minimizing off-target effects and enhancing efficacy. Such innovations underscore the industry's commitment to improving therapeutic outcomes for patients facing complex medical challenges. In another notable development, Novartis has entered into a substantial $3.2 billion licensing agreement with Alteogen, focusing on ALT-B4 hyaluronidase technology. This collaboration emphasizes the growing interest in subcutaneous drug formulations that offer improved patient compliance and convenience compared to traditional intravenous routes. Hyaluronidase helps disperse and absorb subcutaneously injected drugs more efficiently by degrading hyaluronic acid in tissues, thereby enhancing bioavailability and reducing injection volumes. Shifting gears to clinical trial advancements, Hutchmed's combination therapy featuring Tagrisso (osimertinib) and Orpathys (savolitinib) has achieved a Phase 3 success in first-line treatment for MET-overexpressing non-small cell lung cancer. This marks an important stride towards personalized medicine approaches that target specific genetic mutations driving tumor growth. The success of this combination therapy points to a future where targeted treatments become more prevalent in addressing complex oncogenic drivers. In the realm of strategic partnerships, Novacyt and Illumina have embarked on a five-year collaboration focusing on diagnostics and DNA sequencing technologies. This partnership aims to leverage Illumina's genomic sequencing expertise to advance precision medicine efforts in diagnostics, further highlighting the importance of collaborations in overcoming technological hurdles. Meanwhile, in gene therapy developments, NewBiologix and Synastra Biotechnology have joined forces to develop stable recombinant adeno-associated viral cell lines for Duchenne muscular dystrophy therapies. Their partnership aims to address manufacturing challenges associated with gene therapies for rare diseases, potentially accelerating treatment availability for patients in need. Despite these promising advancements, the industry is not without its challenges. Cellares recently announced significant job cuts following the loss of a contract with Bristol Myers Squibb for cell therapy production. Additionally, regulatory scrutiny remains high as evidenced by the UK Medicines and Healthcare products Regulatory Agency's suspension of Amgen's Tavneos amid concerns over trial data integrity. Such developments underscore the critical importance of maintaining rigorous data standards in drug development. Turning our attention to regulatory dynamics, the Trump administration has introduced a new drug pricing model under Medicare, providing weight loss medications at reduced prices for eligible seniors. This initiative involves major players like Eli Lilly and Novo Nordisk and aims to enhance access to obesity treatments for seniors—a move that could signify a shift towards preventive healthcare. On the clinical front, Alnylam Pharmaceuticals' next-generation gene-silencing technology shows promise for treating transthyretin amyloidosis with cardiomyopathy (ATTR-CM). Despite setbacks faced by AstraZeneca and Ionis Pharmaceuticals in similar trials, Alnylam's approach holds potential when used alongside standard treatments. The pharmaceutical sector also sees evolving market dynamics with reverse mergers rising sharply by 1,600% in Q3. This trend rivals traditional IPOs as companies seek alternative routes to liquidity amid fluctuating investor sentiments. Such strategic adaptations reflect the industry's resilience amidst economic uncertainties. In conclusion, these developments paint a picture of an industry dynamically adapting to technological advancements, regulatory changes, and market demands. From innovative drug delivery technologies to strategic partnerships and robust regulatory frameworks, the sector remains committed to advancing precision medicine and improving patient care globally. As these trends continue to unfold, they promise significant implications for drug development processes and therapeutic paradigms across various disease landscapes.Support the show

AI Technologies In Pharma And Biotech: Interview With Bill Wallace #aiinpharma #pharmatechnology #biotechai Hi Everyone! Welcome to the Biotech Bytes by The Swan GroupHow is AI revolutionizing patient safety, clinical trials, and adverse event monitoring? In this exclusive interview with Bill Wallace from Intercept Pharmaceuticals, we explore how AI is transforming pharma and biotech. Please visit our website to get more information: https://swangroup.net/ Learn how AI-powered models are enhancing pharmacovigilance, detecting data anomalies, and improving safety monitoring. Bill shares practical examples, including AI-driven chatbots and strategies to address data security challenges, while highlighting the potential of artificial intelligence in life sciences.Discover how AI is reshaping the future of healthcare with innovative approaches that prioritize data accuracy and patient-first solutions. Watch now to uncover new perspectives on AI's role in the pharmaceutical and biotech industries. Share your thoughts on this game-changing technology in the comments!Specifically, this episode highlights the following themes:✅ The integral role of AI in advancing pharmaceutical research and patient care✅ Confronting cybersecurity challenges in an AI-enhanced pharmaceutical industry✅ Navigating the financial and strategic landscape for AI adoption in varying company sizesLinks from this episode:✅ Get to know more about Bill Wallace: williamwallace2  ✅ Learn more about Intercept: https://www.interceptpharma.com

My client, Jennifer, spent four plus years as a clinical trial manager. Her leadership praised her, handed her work well above her level, and yet, her promotion didn't come. She had become too useful exactly where she was.Jen came into The Right Move Protocol with a one year goal. In just one month she had a promotion she was not expecting. A short time later she identified her ideal role with her dream company. By using the skills she learned and applying her growth mindset she negotiated and accepted an Associate Director position in a therapeutic area she had been trying to get into for years. She did it while her family had more going on than she ever could have anticipated.In this episode, you'll learn:What "developed in place" really means, and why the praise is not progressJen's 90% rule for deciding before you feel readyWhy the part of the program she dreaded is the part that got her results the quickestWhat she says to anyone who thinks her results were luck or timingThe negotiation truth that follows you from job to jobConnect with Jennifer on LinkedIn here.Get the Book: Your Worthy Career: A Science-Backed Method to Build a Meaningful Career in Pharma and Biotech here.Work with Me: Learn more and apply to work with me here.Love the podcast?  Share your feedback by leaving us a review. Thank you!Connect on SocialsLinkedInInstagram

Most drug discovery genomic data comes from a thin slice of the world, and that bias follows every decision downstream. Your team can run a Mendelian randomization study on 35,000 patients and still walk away with a single signal that doesn't even apply to the population you care about. If your phenotype definitions are fuzzy, more data won't save you. Erika Kvikstad is a computational biologist who led precision medicine for cardiovascular disease at Bristol-Myers Squibb, working on therapies including Camzyos for hypertrophic cardiomyopathy. She now works independently on genomic data equity, focused on how reference populations shape everything from target discovery to clinical trial recruitment. You'll get a practical look at how to evaluate real-world data vendors, why heart failure is nearly impossible to define cleanly from billing codes, and where statistical power breaks down even with tens of thousands of patients. Erika also explains how her team used AI to reconstruct missing imaging data and validate cardiomyopathy diagnoses at scale. This episode covers GWAS studies, Mendelian randomization, UK Biobank, proteome-wide analysis, and the practical gap between biobank-scale data and disease-specific cohorts. It's built for data and analytics leaders working in life sciences who need to understand where genomic bias enters their pipeline, not just that it exists. Clarification Around 57:58–58:24, in discussing the proteome-wide Mendelian randomization study, Erika moved quickly between two related findings. BTN3A2 was identified as a candidate associated with ischemic stroke and potential immune-modulatory biology. Separately, single-cell expression data helped contextualize other candidate signals, including some with enriched expression in cardiomyocyte populations. Cardiomyocyte-enriched expression was not a specific finding for BTN3A2. Chapter Markers 00:00 Whose genome are we designing drugs for 01:34 Erika's path from academic genomics to BMS 03:48 Building the precision medicine strategy at BMS 06:37 Ross shares his own HCM diagnosis 07:09 Why heart failure resists clean definition 11:11 How medication use reclassifies patients 14:35 Imaging as a biomarker, and its data gaps 20:23 Data infrastructure gaps across regions 22:44 What to look for when evaluating a data vendor 27:35 Consortia and biobanked specimens for rare mutations 29:52 Cardiovascular data infrastructure versus oncology 32:29 Where statistical power breaks down 37:07 UK Biobank's strengths and its limits 40:01 Bridging broad biobanks with disease-specific cohorts 44:32 How reference population bias propagates downstream 48:53 Where genomic bias hits hardest in the pipeline 53:18 Inside a proteome-wide Mendelian randomization study 59:42 Choosing the right computational tool for the question 1:06:38 Building globally representative genomic infrastructure 1:08:04 Ross's takeaways on bias and statistical power Useful Links & Resources - Erika on LinkedIn: https://www.linkedin.com/in/erikakvikstad - UK Biobank: https://www.ukbiobank.ac.uk - Alliance for Genomic Discovery: https://alliancegenomicdiscovery.org - SHaRe Registry (DCM Foundation): https://dcmfoundation.org Connect With the Show - Ross Katz on LinkedIn: https://www.linkedin.com/in/b-ross-katz/ - (Ross Katz on X: https://x.com/brosskatz - CorrDyn LinkedIn: https://www.linkedin.com/company/corrdyn/ Have you run into genomic reference bias in your own work? Tell us what it looked like and how your team caught it. Visit corrdyn.com to learn how CorrDyn can help your organization extract value from data. Subscribe to Data in Biotech so you don't miss the next conversation.

How can scientists and biotech leaders move forward when the policy and funding landscape keeps shifting beneath their feet?In this episode, host Elaine Hamm, PhD, welcomes back Srinu Sonti, JD, Principal at Lewis-Burke Associates, for an update on the current state of science and healthcare policy. Srinu explores what changes in federal research funding, healthcare policy, and international collaboration could mean for scientists, universities, and early-stage biotech companies – and where opportunities may still be emerging.In this episode, you'll discover:How changes in science funding, healthcare policy, and federal priorities could affect researchers and biotech companies in the months ahead.Why AI, organ-on-a-chip technologies, in silico models, and other new approach methodologies could create new opportunities for research and drug development.How scientists and biotech leaders can advocate for their work by engaging policymakers, communicating their impact, and demonstrating the economic and public health value of scientific innovation.Tune in for a practical look at how scientists and biotech leaders can navigate uncertainty, identify emerging opportunities, and make sure their voices are heard as the science policy landscape continues to evolve.Links: Connect with Srinu Sonti, JD, and learn about Lewis-Burke Associates.Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine.Check out Help a Reporter Out.Check out our previous episode with Srinu.Connect with Ian McLachlan, BIO from the BAYOU producer.Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

In 1987, Mary P. Lovato, a member of Kewa Pueblo in New Mexico, was diagnosed with acute leukemia. To receive a bone marrow transplant, she had to travel more than 800 miles from home because specialized cancer care was unavailable through the Indian Health Service. When she returned, she discovered another obstacle: many in her community feared cancer so deeply that they avoided speaking about it altogether.This episode examines how cancer survivorship exposed profound inequities in the American healthcare system. Long before health equity became a national priority, advocates from underserved communities were confronting disparities rooted in geography, poverty, racism, language, underfunded healthcare systems, and historical mistrust of medical institutions. Their work demonstrated that scientific advances alone cannot improve survival if patients cannot reach, afford, or trust the care available to them.The story follows pioneers including Mary P. Lovato, who built the first national Native-led cancer support and education program for Indigenous communities, and Maimah Karmo, founder of the Tigerlily Foundation, whose breast cancer diagnosis inspired a movement to improve early detection, clinical trial participation, and representation for Black women. Their advocacy challenged longstanding barriers to culturally competent care while highlighting persistent inequities in access to screening, fertility preservation, navigation, and innovative treatments.The episode also explores why diversity in clinical research matters. For decades, many cancer clinical trials disproportionately enrolled White patients, limiting both access to promising therapies and the scientific understanding of how treatments perform across different populations. Researchers, patient advocates, and community leaders responded by redesigning outreach, improving patient navigation, reducing logistical barriers, and insisting that affected communities help shape the research itself.Cancer survivorship cannot be measured solely by scientific breakthroughs. It also depends on whether every patient has a meaningful opportunity to benefit from them. The pursuit of health equity remains one of the defining challenges and enduring responsibilities of modern oncology.RELATED LINKSNational Cancer Institute | Cancer Health Disparities⁠Indian Health Service⁠Tigerlily Foundation⁠National Cancer Institute | Cancer Clinical Trials⁠American Indian Cancer Foundation⁠Abramson Cancer Center | University of Pennsylvania⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What happens when cutting‑edge science meets one of the most devastating pediatric cancers? In this episode of Sounds of Science, Dr. Aled Edwards discusses how open, collaborative research is helping scientists confront rare and fatal childhood cancers like diffuse intrinsic pontine glioma, and what it means when a potential therapy moves closer to reaching children who urgently need it.  Show Notes The Disruptors: Meet Aled Oncology In Vivo Imaging Solutions | Charles River Oncology CRO Services | Charles River Open Science: The Parallel Universe | Podcast A Deadly Brain Cancer in Children | Blog 

In this episode, Simon sits down with Dr. Sherry Zhang, an entrepreneur, molecular geneticist, bestselling author, and pioneer in personalized nutrition.After arriving in the United States from China with just three bags and $3,000, Sherry went on to earn her PhD in molecular biology and build a career at the intersection of science, entrepreneurship, genomics, and longevity.She shares how her scientific curiosity led her from the laboratory into entrepreneurship, the challenges of building a biotech company, and the lessons she learned about fundraising, leadership, hiring, and building the right team.The conversation also explores personalized health, the future of AI-driven longevity research, and what founders can learn from listening deeply to customers and building products around real problems.Whether you're a founder, entrepreneur, scientist, or business leader, this episode delivers powerful insights on curiosity, resilience, innovation, leadership, and turning ambitious ideas into meaningful impact.Key MomentsIntroduction to Dr. Sherry Zhang and her journey from China to the United StatesHow curiosity shaped Sherry's career as a scientist and entrepreneurThe journey from molecular biology to personalized nutritionThe moment Sherry realized her scientific research could help everyday peopleWhy she decided to become a founder and build a companyThe challenges of fundraising and finding the right investorsHow Sherry's leadership style evolved from science to entrepreneurshipWhy founders need to surround themselves with people who share their principlesThe importance of hiring the right talent—and making difficult decisions quicklySherry's top advice for first-time founders: listen deeply to your customersWhy building a focused minimum viable product is essentialHow structured communication can prevent unnecessary meetingsThe future of AI, systems biology, and personalized longevityWhat's next for Sherry and her work in health optimizationTo learn more about Sherry Zhang, please visit her LinkedIn profileTo learn more about GenoPalate, please visit her website.YOUR HOST - SIMON LADER    Simon Lader is the host of The Conference Room, Co-Founder of global executive search firm Salisi Human Capital, and lead generation consultancy Flow and Scale. Since 1997, Simon has helped cybersecurity vendors to build highly effective teams, and since 2022, he has helped people create consistent revenue through consistent lead generation. Get to know more about Simon at:    Website: https://simonlader.com/  Twitter: https://twitter.com/simonlader  LinkedIn: https://www.linkedin.com/in/headhuntersimonlader/    The Conference Room is available onSpotifyApple podcastsAmazon MusicIHeartRadio

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Olivier Litzka, Partner at Andera Partners, talks about what it really takes for biotech companies to attract capital, stay focused, and survive the moments when biology and execution punch back. Olivia also discusses a collaborative effort in Europe to create a stronger public market and investor base, and what the emergence of AI and Chinese biotech means for building tomorrow's biotech companies. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Biotech has delivered one of its strongest rallies in years, fueled by a resurgence in M&A activity, improving sentiment and continued innovation. But as valuations rise and competition intensifies, investors are becoming increasingly selective. RBC's biotech analysts explore the key drivers behind the rally, the outlook for M&A, the growing role of China and what could determine whether the sector sustains momentum through the second half of the year.Key PointsM&A activity, improving regulatory sentiment and strong clinical data have helped drive a significant re-rating across biotech. Higher valuations have boosted investor confidence but may leave less room for error in the second half. Innovation continues to underpin long-term growth opportunities, although competition is increasing.China's growing role in drug development is reshaping competitive dynamics and business development strategies. Investors are becoming increasingly selective, with a greater focus on company-specific catalysts and fundamentals.Chapter MarkersWhat's driving biotech's rally? [00:52) Brian Abrahams explores the key factors behind biotech's resurgence..Why selectivity matters more now [2:30] Rising valuations have strengthened confidence across biotech, but investors may need to become more discerning about where they allocate capital in the second half.The outlook for biotech M&A [4:02] M&A remains a leading catalyst for biotech investors, with deal activity continuing to shape sentiment and sector performance. What the biotech investor survey revealed [7:11] Lisa Walter discusses investor positioning, valuation expectations and why enthusiasm remains constructive despite a more neutral stance following the rally. Innovation, drug launches and competitive advantage [11:02] Leonid Timashev explores how innovation, commercial execution and emerging modalities are shaping competitive advantage in biotech, and why successful launches remain critical to long-term value creation.China's growing influence in biotech [17:44] China's emergence as a leading source of innovation and business development activity is reshaping competitive dynamics across the biotech sector.What could drive the second half? [20:15] RBC analysts discuss the factors most likely to determine whether biotech can sustain its momentum.

In this episode, Seth sits down with Lourdes Felix, CEO & CFO of BioCorRx, to discuss what it really takes to build and lead a publicly traded biotech company focused on substance use disorder.Lourdes shares her journey from finance professional to CEO, her 14+ years with BioCorRx, and how the company has evolved from a reverse merger into a drug-development business working on innovative addiction treatment solutions.They discuss the realities of running a public biotech company, from raising capital and managing investor expectations to navigating clinical trials, regulatory development, and the challenge of being pre-revenue. Lourdes also explains BioCorRx's approach to medication-assisted treatment and the company's naltrexone implant technology.The conversation also gets personal, exploring the patients and families who have been impacted by the company's work and what continues to motivate Lourdes after more than a decade in the industry.Finally, Lourdes discusses BioCorRx's first revenue-generating commercial asset and what could be next for the company.Subscribe for more conversations with founders, CFOs, and advisors shaping today's capital markets.00:00 — Introducing Lourdes Felix & BioCorRx 01:42 — Building a Company Around Addiction Treatment 03:52 — How BioCorRx Helps People With Addiction 05:59 — From Finance Professional to CEO 07:43 — Balancing Business With Capital Raising 10:43 — From Finance to the World of Biotech 11:50 — Developing BioCorRx's Naltrexone Implant 15:18 — The Biggest Misconceptions About Addiction 18:26 — The Patients Who Keep Her Going 19:34 — BioCorRx's First Revenue-Generating Asset & What's Next Connect with Seth LinkedIn – https://www.linkedin.com/in/sethfarbman/ Instagram – https://www.instagram.com/sethfarbmanstock TikTok – https://www.tiktok.com/@sethfarbman Twitter (X) – https://x.com/sethfarbman1

Deux tiers des maladies connues n'ont aucun traitement efficace.Pourtant, les géants de la pharma ont arrêté de chercher.D'ici 2033, l'industrie pharmaceutique mondiale perdra 400 milliards de dollars de chiffre d'affaires par an, à mesure que ses brevets tombent dans le domaine public.Aujourd'hui, plus de 70% des médicaments innovants vendus viennent de petites entreprises, des biotechs, qu'elle rachète pour combler ce trou.C'est ici que Rafaèle Tordjman a décidé d'agir.Double docteure en médecine et en sciences, elle a soigné des cancers du sang à Saint-Louis et à Necker, avant de passer une thèse de sciences et un post-doctorat à l'Inserm.Après ses études, Rafaèle quitte l'hôpital car elle comprend que pour mieux servir les patients, il faut accélérer l'innovation.Mais cette innovation ne naît ni dans les hôpitaux, ni chez les géants de l'industrie.Elle naît dans les petites biotechs.Alors en 2018, elle fonde Jeito Capital pour accompagner ces structures.Aujourd'hui, Jeito gère 1,6 milliard d'euros et est devenu le plus gros fonds biopharma indépendant d'Europe.Pendant deux heures trente, Rafaèle décrypte une industrie qu'on ne nous explique jamais :Pourquoi les géants de la pharma ont arrêté de chercher et rachètent les molécules des petites biotechs à coups de milliardsCe que la Chine a déjà craqué sur le médicament, et la carte qui reste à jouer pour l'EuropePourquoi certains médicaments n'existeront jamais, même quand la maladie tueLes vrais chiffres derrière chaque médicament sur le marchéLes maladies du siècle et comment les prévenirUne plongée dans le modèle économique du médicament, racontée par une femme qui l'observe des deux côtés : au chevet du patient, et au capital des entreprises qui le soignent.Vous pouvez contacter Rafaèle sur Linkedin.TIMELINE:00:00:00 - Deux tiers des maladies sont sans traitement 00:13:17 - Le problème avec la chimiothérapie 00:18:41 - Financer les médicaments que les géants rachètent des milliards 00:27:00 - Le calendrier des brevets décide tout 00:34:31 - Concevoir un fonds comme une entreprise 00:42:29 - Les chiffres derrière chaque médicament sur le marché 00:55:31 - Transforme sa thèse de doctorat en entreprise 01:01:57 - 70 % de l'innovation ne vient pas des big pharma 01:11:19 - RGPD, le boulet de l'innovation médicale 01:25:06 - La santé, un secteur sans cycle et sans bulle 01:31:58 - Pourquoi certains médicaments n'existeront jamais 01:44:31 - Les maladies du siècle 01:54:45 - Les chiffres derrière un fonds biopharma d'un milliard 02:03:18 - L'œil humain reste indispensable 02:16:00 - 80 % des décisions de santé dans les familles sont prises par des femmes 02:25:27 - Le polar pour comprendre l'industrie du médicamentLes anciens épisodes de GDIY mentionnés : #543 - Yann Le Cun - AMI Labs - Rendre l'IA plus humaine#507 - Laurent Alexandre - Vers la fin des études supérieures ?#426 - Thomas Clozel - Owkin - Comment casser Big Pharma grâce à l'IA#397 - Yann Le Cun - Chief AI Scientist chez Meta - L'Intelligence Artificielle Générale ne viendra pas de Chat GPT#372 - Alexandre Jenny - Pixfield - L'incroyable histoire du geek de Chambéry derrière la GoPro 360#327 - Laurent Alexandre - Auteur - ChatGPT & IA : "Dans 6 mois, il sera trop tard pour s'y intéresser"#165 - Laurent Alexandre - Doctissimo - La nécessité d'affirmer ses idéesNous avons parlé de :JeitoDr. HouseKeytrudaOVNI CapitalMécanismes de l'effet placebo et du conditionnementQu'est ce qu'un essai en double aveugle ?Institut PasteurDASSAULT : le Fleuron de la défense FrançaiseUS Food and Drug AdmninistrationComment la Chine est devenue imbattable ?Les recommandations de lecture :For Blood and Money: Billionaires, Biotech, and the Quest for a Blockbuster Drug, by Nathan Vardi

In 2000, Katie Couric underwent a live colonoscopy on national television following the death of her husband, Jay Monahan, from colorectal cancer at age 42. The broadcast demystified a procedure many Americans feared, led to an estimated 20% increase in colonoscopy screenings, and became one of the clearest examples of how public storytelling can change healthcare behavior.This episode examines how celebrities, journalists, filmmakers, and entertainers helped reshape the public conversation about cancer during a period when survivorship was becoming increasingly visible. As breakthroughs in targeted therapies, immunotherapy, and early detection allowed more people to live beyond cancer, public figures used their platforms to encourage screening, reduce stigma, and accelerate research. Their influence extended far beyond awareness campaigns, helping transform cancer from a private diagnosis into a national public health conversation.Central to this story is Laura Ziskin, the Hollywood producer behind Pretty Woman and the Spider-Man films, whose metastatic breast cancer diagnosis inspired the creation of Stand Up To Cancer. Working alongside Couric and leaders from entertainment, journalism, and biomedical research, Ziskin championed a new funding model that required multidisciplinary scientific collaboration, helping accelerate discoveries that contributed to multiple FDA-approved cancer therapies. The episode also highlights the advocacy of actor Patrick Dempsey, whose family's experience with ovarian cancer led to the creation of the Dempsey Center, expanding support for patients and caregivers beyond medical treatment.The story also asks what celebrity advocacy often leaves unsaid. Financial toxicity, caregiver burden, chronic pain, mental health, and the long-term effects of treatment rarely receive the same attention as dramatic diagnoses or breakthrough cures. As cancer survivorship continues to evolve, the greatest challenge may not be convincing people to care about cancer, but helping them understand what it truly means to live with and beyond it.RELATED LINKSStand Up To Cancer⁠Katie Couric Media⁠Dempsey Center⁠American Association for Cancer Research⁠National Cancer Institute⁠Dana-Farber Cancer Institute | Adult Survivorship Program⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In 2006, a landmark report titled Closing the Gap: Research and Care Imperatives for Adolescents and Young Adults with Cancer confirmed what young survivors had been saying for years. While survival rates for children and older adults had steadily improved, adolescents and young adults had experienced decades of stalled progress. They had become cancer's lost generation.This episode explores how young adult survivors transformed their shared isolation into one of the most influential grassroots movements in cancer advocacy. Diagnosed during the years typically devoted to education, careers, relationships, and starting families, patients between the ages of 15 and 39 confronted challenges that extended far beyond treatment. Fertility preservation, sexual health, employment, financial toxicity, insurance, and long-term quality of life were rarely discussed in oncology clinics, leaving many to navigate survivorship alone.The episode follows advocates including Tamika Felder, Lindsay Avner, Heidi Adams, Doug Ulman, and Dr. Archie Bleyer, whose research and advocacy fundamentally changed how medicine understands adolescent and young adult cancer. Through organizations including Planet Cancer, Fertile Hope, the Lance Armstrong Foundation, and later Stupid Cancer, survivors built online communities, educational resources, conferences, and national partnerships that challenged long-standing assumptions about cancer care. Their work helped establish fertility preservation as a standard discussion before treatment, expanded research dedicated to adolescent and young adult oncology, and elevated quality of life as a critical clinical outcome alongside survival.The movement also demonstrated the power of lived experience to reshape medicine. Survivors became researchers, educators, nonprofit founders, and policy advocates, insisting that cancer care account not only for years of life saved, but for the lives patients hoped to build afterward.What began as a search for peers evolved into a national movement that permanently transformed adolescent and young adult oncology. Today, dedicated research programs, clinical fellowships, survivorship resources, and patient advocacy organizations continue to build on the foundation these young cancer mavericks created.RELATED LINKSNational Cancer Institute | Adolescent and Young Adult (AYA) Cancer Program⁠Closing the Gap: Research and Care Imperatives for Adolescents and Young Adults with Cancer⁠American Society of Clinical Oncology | Fertility Preservation Guidelines⁠Stupid Cancer⁠Livestrong Foundation⁠Journal of Adolescent and Young Adult Oncology⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.